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ABSTRACT 
Treatment of Duchenne Muscular Dystrophy with Exon Skipping Antisense 
Oligonucleotides using Novel Polyethylenimine Carriers  
Shashank Ramesh Sirsi 
Gordon J. Lutz, PhD 
and Margaret A. Wheatley, PhD 
 
 Duchenne muscular dystrophy (DMD) is a lethal disorder that is caused by mutations in the gene 
encoding the dystrophin protein. It has been established that exon skipping oligonucleotides (ESOs) are 
able to ameliorate the symptoms of DMD by modulating dystrophin pre-mRNA transcript splicing 
resulting in removal of the mutated exon from the mRNA transcript. It is estimated that up to 75% of 
DMD cases may be treatable using this ESO-based approach. However, the main obstacle that has limited 
the usefulness of ESOs in treatment of DMD, and most other diseases, is a lack of adequate carriers that 
enable ESO delivery to the target cell nuclei.  Thus,  for the ESO-based approach to ultimately provide 
clinical benefit in treating DMD, it is essential that new compounds be developed that improve the 
efficiency of ESO delivery to myonuclei. 
 In this project, amine rich poly(ethylene imine) (PEI) based compounds were developed to 
improve the delivery of ESO’s to myonuclei of dystrophin-null muscle and recover the dystrophin 
protein. PEI is considered one of the most potent non-viral agents for nucleotide delivery; however, the 
feasibility of PEI-based compounds for the transfection of mature skeletal muscle has not been 
established. Alone, PEI is considered to be a cytotoxic compound, but the biocompatibility of PEI is 
significantly improved by incorporating nonionic linear polyethylene glycol (PEG) polymers into PEG-
PEI copolymers. This project demonstrates that PEG-PEI compounds are potent and versatile vectors 
capable of delivering ESO’s to skeletal muscle in vitro and in vivo. The PEG-PEI based compounds 
developed in this work serve as a platform for developing even more potent “next generation” PEG-PEI 
compounds that have a realistic potential for treatment of DMD. 
 
 
  
xi
 
 
 
 
  
1
Introduction - Overview of Research Project 
 Oligonucleotides composed of 2’O-methyl substitutions on a phosphorothioate 
backbone (2’OMeAO) are promising compounds that function by modulating pre-
mRNA splicing of the target gene, and may be used to modulate alternative RNA 
splicing, mitigate defective splicing, and skip exons.  Thus, 2’OMeAOs have far 
ranging potential as therapeutics for numerous diseases.  Duchenne muscular dystrophy 
(DMD), which is caused by mutations in the gene encoding dystrophin, has been 
established as an excellent candidate for oligonucleotide-based treatment.  Specifically, 
oligonucleotides of 2’OMe, phosphorodiamidate morpholino (PMO), and peptide 
nucleic acid (PNA) chemistries have been shown to facilitate "skipping" of targeted 
exons in the dystrophin gene that either encode early termination codons or contain 
frame-shift insertions or deletions.  Studies, both in vitro and in vivo, with these types of 
exon skipping oligonucleotides (ESOs) have documented production of nearly full-
length dystrophin proteins.  Overall, these studies have led to the prediction that up to 
75% of DMD patients could benefit from an ESO-based treatment..  However, the main 
obstacle that has limited the usefulness of ESOs in treatment of DMD, and most other 
diseases, is a lack of adequate carriers that enable ESO delivery to the target cell nuclei.  
Thus, for the ESO-based approach to ultimately provide clinical benefit in treating 
DMD, it is essential that new compounds be developed that improve the efficiency of 
ESO delivery to myonuclei. 
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 The amine rich polymer poly(ethylene imine) (PEI) is established as an efficient 
nucleotide carrier due to its cationic nature, enabling it to bind both to the negatively-
charged phosphate backbone of nucleotides and negatively-charged elements of cell 
membranes, facilitating endocytotic uptake of PEI-nucleotide complexes into cells. The 
functionality of PEI as a nucleotide carrier is significantly improved by incorporating a 
nonionic linear polymer polyethylene glycol (PEG) into PEG-PEI copolymers. Overall, 
PEG-PEI copolymers represent a flexible nucleotide delivery system with controllable 
size and surface charge, adjustable unpackaging properties in cells, and flexibility for 
addition of moieties that target specific entities on cell membranes. 
 The overall goal of this study was to develop improved PEI-based synthetic 
polymers that facilitate efficient delivery of ESO’s to myonuclei of muscle fibers from  
mdx mice (the classical murine model of DMD), using both in vitro and in vivo 
approaches, and to demonstrate high levels of dystrophin expression. The initial goal of 
this project (Chapter 2) was to establish PEG-PEI copolymers as suitable agents for the 
delivery of ESO’s to myonuclei of mature skeletal muscle cells in culture. The second 
goal of this study (Chapter 3) was to evaluate the in vivo efficacy of PEG-PEI 
compounds for delivering ESO’s to skeletal limb muscles. The final goal of this study 
(Chapter 4) was to develop a system for encapsulating PEG-PEI-ESO polyplexes into 
nanosvesicles which would shield the surface properties, allow for sustained realease of 
ESO, and potentially increase the in vivo efficacy of cationic PEG-PEI based 
polyplexes. 
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 The results of this study demonstrate the feasibility of PEG-PEI as viable 
transfection agents for the delivery of ESO’s to skeletal muscle. The versatility of PEG-
PEI copolymers allows the physical properties of the polymer to be adjusted and 
modified with targeting ligands for improved ESO delivery, both in vivo and in vitro, 
and to produce functional levels of dystrophin in mdx mice at therapeutic levels needed 
to ameliorate the symptoms of DMD. Overall, this research provides a platform for the 
development of “next generation” PEG-PEI compounds that may be more suitable for 
in vivo delivery and produce high levels of dystrophin expression for clinical treatment 
of DMD.     
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CHAPTER 1:  BACKGROUND AND SIGNIFICANCE 
 
I. Duchenne Muscular Dystrophy and the Dystrophin Protein 
 Duchenne muscular dystrophy (DMD) is the most common fatal genetically 
heritable disorder afflicting 1 of 3500 males world-wide [1, 2]. DMD is an x-linked 
heritable disease caused by a mutation in the gene that encodes the dystrophin protein. 
The dystrophin gene is the largest in the human body comprised of over 1.4 mB, 
making it very susceptible to mutations [3]. Mutations along the length of the gene 
cause a disruption in the reading frame (or “frame shift”) that induce transcription of an 
early stop-codon, resulting in a truncated non-functional dystrophin protein. Research 
on the dystrophin gene has identified numerous point mutations that have made it 
possible to predict the clinical progression of DMD in over 93% of cases [4].  
 Dystrophin is a cystoskeltal associated protein (427 kDa) that forms a structural 
linkage between the dystroglycan complex (DGC) at the muscle cell membrane and 
cytoskeletal actin (Figure 1-1). Dystrophin is a rod shaped protein, measuring about 
150 nm in length, and consisting of 3684 amino acids. Most of the dystrophin structure 
is comprised of spectrin-like triple helical elements that exist in the “central rod” 
domain (Figure 1-2).   While the precise function of the dystrophin protein is not 
entirely clear, it appears to have a critical role in stabilizing the DGC. Loss of the 
dystrophin protein is always associated with a loss of the entire DGC, which in-turn  
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Figure 1-1. (Chamberlain, J.S. Human Molecular Genetics, 2002, Vol. 11, 
No. 20 2355–2362) Illustration of the dystrophin protein and its interaction 
with actin and dystroglycan complex. 
Actin binding Central rod domain Carboxy Terminal 
domain 
Cystein rich
Figure 1-2. (Chamberlain, J.S. Human Molecular Genetics, 2002, Vol. 11, 
No. 20 2355–2362) Illustration of the open reading frame of the dystrophin 
protein. The 427 kDa protein consists of four domains, namely the actin 
binding domain, central rod domain, cystein rich domain and the carboxy-
terminal domain. The majority of the protein is composed of 24 spectrin like 
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induces instability in the muscle cell membrane leading to persistent muscle injury 
following contractions [5, 6]. DMD is the most severe form of muscular dystrophy and 
is associated with the loss of the entire dystrophin protein leading to progressive muscle 
degeneration. Patients afflicted with DMD rarely live past thirty years of age and 
usually succumb to respiratory and cardiac failure in their early twenties. Despite the in-
depth knowledge of the pathology of this disease, currently there remains no effective 
therapeutic options for DMD. 
 
II Approaches for treating DMD; gene therapy versus exon skipping  
 The development of a strain of mice (mdx), arising from a spontaneous mutation 
in inbred C57BL mice, has made it possible to study the effects and potential treatments 
of DMD. The mutation is an X chromosome-linked point mutation on exon 23 of the 
mouse dystrophin gene that causes an occurrence of a premature stop codon and loss of 
the dystrophin protein. Thus, mdx mice are dystrophin null. Although not as severe as 
for humans, the phenotype and pathology of mdx mice is similar to DMD in humans 
making these mice a worthy animal model of DMD. Many approaches to DMD 
treatment utilize this model to test for functionally recovered dystrophin protein.   
 
Viral Vectors 
 Due to the large size of the dystrophin protein, introducing a full length 
replacement gene is a daunting task. Viral vectors are the most efficient gene delivery 
vehicles commonly used to introduce genes into host cells [7]. Viral vectors are very 
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efficient at delivering full length dystrophin genes and have been shown to reduce the 
myopathic phenotype of DMD [8]. While these vectors have shown high levels of gene 
expression, they are known to illicit severe immune responses and may have other 
longterm potential side affects [9-11], making this approach less desirable for clinical 
applications. Viral associated vectors, such as adeno associated virus (AAV) that are 
thought to be safer and still efficient at introducing genes into cells, but have limited 
loading capacities (5 kb) and are not practical for introducing genes to express the full 
length of dystrophin (14 kb) [2]. AAV vectors do, however, show promise due to their 
ablity to introduce smaller genes that encode truncated versions of the dystrophin 
protein.  
 
Mini and microdystrophins 
 To overcome the size limitations of delivering full length dystrophin genes, 
smaller genes that express truncated versions of the protein are being utilized. These 
truncated versions of dystrophin, known as “minidystrophins” or “microdystophins”, 
generally exclude large portions of the central rod domain that make up a significant 
portion of the protein. Genes that express these minidystrophins are much smaller in 
size (<4 kb) and able to package within most AAV vectors [2].  Interestingly, 
expression of these truncated proteins has been shown to partially ameliorate the 
pathological symptoms of DMD, restore the DGC, and considerable increase in the 
level of muscle contractility without injury [1, 2, 12]. Studies have shown that deletions 
up to 46% of the dystrophin protein can still produce truncated dystrophin that partially 
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mitigates the symptoms of DMD [3]. The pathology of treated muscle, where the 
recovered dystrophin proteins are functional yet truncated, has been compared to a 
milder form of muscular dystrophy known as “Beckers Muscular Dystrophy” (BMD). 
Mutations of the dystrophin gene in BMD patients are generally in areas that encode the 
central rod domain and the resulting dystrophin protein is smaller (centrally deleted), 
but still “in-frame” [3, 4, 13, 14].  Patients with BMD generally live their normal life 
span and show little to no adverse reactions due to their disease. Currently, the 
expression of minidystrophins as a treatment for DMD using AAV vectors is in a trial 
phase, however, concerns about long term safety and cost of using these viral vectors 
remain unsolved [15-19].  
 
Exon Skipping using Antisense Oligonucleotides for treatment of DMD 
  The use of antisense oligonucleotides (AO’s) to mediate “exon skipping” for 
the treatment of DMD is currently one of the most promising options for clinical 
therapy. The idea behind this approach is to modulate the splicing of pre-mRNA that is 
transcribed from the dystrophin gene to exclude exons which contain mutations that 
induces a frame shift and premature stop-codon. Exon skipping antisense 
oligonucleotides (ESO’s) can be designed to bind to the intron-exon border of selected 
exons in dystrophin pre-mRNA, blocking splice enhancer sites and causing selective 
removal of exons from the mRNA transcript, an entirely different mechanism than 
classical antisense (Figure 1-3). This technique has repeatedly been shown to skip 
desired exons of the dystrophin gene to produce truncated, but presumably  
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Figure 1-3. Schematic of exon skipping approach in mdx mice. A) Exon 23 of 
the dystrophin gene contains a point mutation that causes a premature stop 
codon during translation of the dystrophin protein. This results in a non-
functional dystrophin protein. B) Exon skipping AO’s bind to the intron exon 
border of exon 23 on pre-mRNA and cause selective removal of the mutated 
exon. This results in a nearly full length and functional dystrophin protein 
E23 
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 functional versions of the dystrophin protein [20-25]. 
 ESO’s have several advantages over minidystrophin genes that make them more 
advantageous for treatment of DMD. ESO’s utilize the existing dystrophin gene and 
modulate the splicing of pre-mRNA rather than introducing artificially constructed 
genes.  The size of the antisense oligonucleotides is much smaller, usually around 20 
nucleotide bases, compared to minidystrophin genes which can be as high as 4 kbp. The 
small size of the oligonucleotides is more advantageous for delivery into cells and 
eliminates packing concerns with the use of AAV vectors. In fact, AAV vector 
expressing antisense sequences linked to a modified U7 small nuclear RNA have 
reportedly produced functional dystrophin in entire groups of muscles and the 
correction of the muscular dystrophy [26]. Additionally, in the exon skipping approach, 
only a single exon is removed, which can correspond to less than 100 amino acids. 
 
Conclusions of viral based gene therapy 
 The identification and characterization of BMD, along with the discovery of 
mini and microdystrophins, has clearly demonstrated that the lethal symptoms of DMD 
can be ameliorated by even partial restoration of the dystrophin protein. While 
introduction of minidystrophins and exon skipping U7 RNA is a powerful approach, 
concerns about the safety of viral vectors and the long term effects of using severely 
truncated dystrophin proteins should not be ignored. 
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III Non-viral Gene therapy 
 In order to overcome the potential longterm safety issues associated with viral 
vectors, a large emphasis has been placed on the development of non-viral methods of 
treating DMD and other genetic disorders. Plasmid DNA’s encoding the full length of 
the dystrophin protein can be introduced to skeletal muscle as a form of treatment. 
However,  the large size of plasmids and the negative charge of the nucleic acid 
backbone severally impede their internalization and delivery to the cell nucleus [9, 27-
29] even using cell penetrating techniques such as electroporation or soniporation [30-
34].  AO’s used for the exon skipping approach are much more efficient at entering 
cells and localizing to the nucleus due to their smaller size. Still, the negative charge 
and susceptibility to degradation have limited their usefulness in vivo.       
 
Synthetic ESO’s for non-viral treatment of DMD    
 Over the past decade, a host of chemical modifications to the basic structure of 
small  AO’s has greatly expanded their target specificity, functionality, and resistance to 
degradation, and thus markedly improved their potential usefulness [35-41]. Chemically 
modified AO’s are becoming increasingly valuable agents for gaining knowledge of 
protein function from genomic and proteomic studies [38, 40] as well as treating genetic 
disorders through regulation of transcript expression, modulations of alternative 
splicing, and exon skipping [38, 40, 42-44]  
 ESO’s  composed of 2’O-methyl substitutions on a phosphorothioate backbone 
(2’OMeAO) are promising compounds that show dramatic improvement in stability and 
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resistance to nuclease degradation compared to original first generation antisense 
phosphorthioate oligonucleotides [36].  In particular, 2’OMeAO’s show negligible 
activity in recruiting RNaseH and function by modulating pre-mRNA splicing by steric 
inhibition of spliceosomal proteins. Despite their increased stability, 2’OMeAO’s have 
remained mostly ineffective as a therapeutic option for DMD patients primarily due to 
their poor delivery profile.  2’OMeAO’s, like unmodified ESO’s, contain a negatively 
charged backbone that may be restrict uptake into cells, and therefore these compounds 
require carriers to facilitate their delivery into target cells. Recent reports have focused 
on oligonucleotide analogues such as PMO or PNA as alternatives to 2OMeAO’s, 
suggesting the uncharged backbones result in superior stability and lack the necessity of 
a carrier [25, 45-51]. Still, significant amounts of PMO and PNA oligonucleotides 
analogues are required to have a therapeutic effect. It is clear that PMO’s and PNA’s are 
superior to 2OMeAO’s without a carrier, however carrier assisted 2OMeAO’s still have 
tremendous potential for efficient target specific delivery for treating DMD.  
 
Carriers for nucleic acid  delivery 
    All nucleic acid agents including plasmid DNA and various oligonucleotides 
appear to require carriers to facilitate delivery in vivo. The two major non-viral carriers 
used for nucleic acid delivery are phospholipid based liposomes or cationic polymers 
that electrostatically bind the nucleic acid backbone. Both of these types of vectors have 
shown dramatic improvement in the cellular uptake of nucleic acids in cultured cells 
and have their unique advantages as gene therapy vehicles.  
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Liposomes 
 Liposomes are commonly used vectors for in vivo drug delivery applications 
[52, 53]. Liposome complexes are spherical vesicles, typically 100 - 200 nm in 
diameter, that are formed through hydrophobic interaction of phospholipids and 
cholesterol subunits. The structure forms a cell membrane like bilayer and an aqueous 
core that can entrap hydrophilic molecules, including nucleic acid based compounds 
[28, 54, 55]. Cationic liposomes comprised of positively charged phospholipids 
subunits are more commonly used for gene delivery applications, due to their ability to 
electrostatically bind negatively charged nucleic acids ( forming a structure known as a 
“lipoplex”) and facilitate its cellular uptake into cells [56-59]. Despite the wide variety 
of liposomes that have been synthesized and tested over the past 2 decades, advances in 
gene delivery using these vectors have only been improved modestly and in vivo gene 
delivery using these vectors are predominantly effective only in specific organs such as 
the lungs and  liver [57, 60-62]. 
   
Cationic Polymers 
The use of synthetic polymers as transfection agents is another major approach 
to gene delivery. Cationic polymers can electrostatically bind to nucleic acids forming 
small nanoscale sized structures commonly referred to as “polyplexes”. These polymers 
form stable structures with nucleic acids, surrounding and condensing them in a manner 
that protects them from enzymatic degradation and facilitates their uptake into cells [63-
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66]. There are a wide variety of polymers available that have been used as transfection 
agents. Most of these polymers utilize native or chemically modified polyamine 
compounds such as chitosan [67, 68], poly-L-lysine (PLL) [68-71], or (the most potent 
transfection agent) polyethylenimine (PEI) [64, 66, 72-75].   
The major advantage to using non-viral vectors is that they can be comprised of 
a wide variety of materials that may not elicit an immunogenic response in the human 
body [9] [64]. Synthetic vectors are also easily produced in a wide variety of shapes and 
sizes that can be tailored at the molecular level. The major drawback of using non-viral 
vectors, however, has continuously been the low levels of transfection efficiency [9, 28, 
64, 76]. There is a strong effort at the present time to identify and overcome the 
obstacles associated with non-viral gene delivery in order to produce synthetic 
compounds with transfection efficiencies comparable to those of viral vectors, which is 
the major focus of this research project.  
 
Cellular barriers to non-viral gene therapy treatments 
 Several barriers to efficient gene delivery using cationic polymers need to be 
addressed for clinical application of non-viral vectors to be realized. The most 
prominent barriers are considered to be 1) the physical stability of the nucleic acid 
carrier complex in the extracellular environment, 2) internalization of the nucleic acid 
carrier 3) endosomal escape of the internalized nucleic acid carrier into the cystoplasm, 
and 4) separation of the nucleic acid from its carrier and internalization into the cell 
nucleus [76]. 
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Nucleic Acid-complex stability 
 The physical interaction of nucleic acids and cationic vectors is implicated with 
the condensation and protection of nucleic acids from nucleases in the extracellular 
environment [64, 76] as well as facilitating  interaction with the cell membrane. The 
components of the extracellular environment may, however, have significant 
consequences on the physical stability of polyplexes. Specifically, negatively charged 
proteins can interact with positively charged polymers that may destabilize the 
interaction with nucleic acids and severely impede gene transfection [76]. Additionally, 
interactions between the individual nucleic acid-complex particles can occur that 
potentially cause aggregation, especially in high salt concentrations as within the body 
[77]. Aggregation of particles can affect their ability to enter the cell and significantly 
affect the transfection efficiency of nucleic acid compounds [76]. Physiochemical and 
stability analysis of the nucleic acid complexes is essential for designing improved 
delivery vehicles and plays an even more critical role in determining their in vivo 
efficacy.         
 
 Cellular Internalization 
The internalization of nucleic acid polyplexes is a critical process for therapeutic 
gene delivery and has been widely studied in a variety of cell lines [59, 72, 73, 78-80]. 
Despite the extensive literature on macromolecule uptake, the specific details on the 
mechanisms of internalization and vesicle trafficking are poorly understood [76, 81]. It 
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is generally accepted that internalization of polyplexes is regulated by both clathrin- and 
caveolin-mediated processes [78], both of which are dependent on the macromolecular 
properties of the structure being internalized and the cell type. Importantly, this process 
has previously been shown to be stimulated using cell surface receptor-specific ligands, 
which has had significant impact on designing non-viral nucleic acid delivery vectors 
[9, 28, 82-86]. 
 
Endosomal Escape 
The inability of cationic polymers and cargo to escape the endosomal 
compartments is a limiting step to non-viral molecular therapy. After a nucleic acid-
vector complexes are internalized, a complex internal trafficking system routes the 
endosomal vesicles to sorting endosomes or recycling endosomes that redirect materials 
back to the cell surface. [87, 88]. Material that is not internalized is presumably 
sequestered to lysosome compartments where the nucleic acids are then degraded [9]. 
Nucleic acid-vector complexes must escape the endosomal compartments in order to 
prevent their digestion and migrate to the cell nucleus. The mechanism of release due to 
cationic polyplexes, is a topic that is still being debated [9]. Some studies argue that the 
simple association of the cationic polyplexes to the negatively charged endosmal 
membrane is enough to induce membrane disruption [89], however,  a widely accepted 
alternative theory, known as the “Proton-Sponge” effect [66], attributes the disruption 
of endosomal or lysosomal compartments to osmotic swelling induced by protonatable 
cationic polymers. More specifically, endosomes and lysosomes both have V-ATPase 
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proton pumps meant to acidify the compartments which results in an influx of 
accompanying chloride ions. Protonatable polymers act as a buffer that prevents 
acidification. To maintain the lower pH, increased proton pump activity is required 
which causes a greater influx of chloride ions. The change in osmotic gradient due to 
the increased ion concentration causes an influx of water and swelling of the endosomal 
and lysosomal compartments which may lead to eventual compartment rupture. The 
exact mechanism of endosomal escape using cationic polyplexes is still being contested 
[9], however it is generally accepted that cationic polyplexes significantly enhance 
endosomal rupture and release of nucleic acid compunds into the cytoplasm. 
 
Nuclear Localization 
Release of the nucleic acid compounds from their carrier and their subsequent 
nuclear localization is another barrier to gene delivery that needs to be addressed in 
designing molecular therapy vectors. Dissociation of nucleic acids from delivery 
systems is often overlooked as it is a difficult event to observe. Current approaches to 
controlling dissociation behavior involve utilizing pH sensitive or enzymatically 
cleavable polymers that are assumed to degrade or release nucleic acids in endosomal or 
lysosomal compartments [63, 90]. After nucleic acids dissociates from their carrier, they 
must then be transported to the nucleus. Passive entry of large nucleic acid compounds, 
such as plasmid DNA, is unlikely and requires active transport through nuclear pores, 
which is aided by the use of nuclear localization signals (NLS) [81]. This process is of 
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less concern when trying to deliver small oligonucleotides which are better able to 
diffuse through the cell and localize to the nucleus.    
 
Overcoming gene therapy barriers using PEI 
The amine rich polymer poly(ethylene imine) (PEI) is established as an efficient 
nucleotide carrier due to its cationic and highly protonatable nature, enabling 
endocytotic uptake of PEI based polyplexes into cells [64, 66, 72-75]. Compared to 
other cationic vectors, PEI is thought to provide much more efficient endosomal escape 
by the “proton-sponge effect” [66, 91-93], facilitating the escape of nucleic acids and 
their delivery to the cell nucleus. The functionality of PEI as a nucleic acid carrier is 
significantly improved by incorporating a nonionic linear polymer polyethylene glycol 
(PEG) into PEG-PEI copolymers [94-96], reducing cytotoxicity and improving 
biocompatibility. An illustration of the presumed mechanism for PEG-PEI-ESO 
delivery is outlined in Figure 1-4. Additional improvements to transfection efficiency 
of PEI-based carriers have been demonstrated in cultured cells using a variety of surface 
modifications meant to stimulate endocytotic uptake or enhance cell surface ligation 
[74, 86, 91, 97-101]. In vivo application of PEG-PEI copolymers is more limited, but 
several studies have investigated PEI based carriers as potential vectors for gene therapy 
applications [74, 83, 85, 86, 102, 103]. Most of these studies are focused on localized in 
vivo delivery or systemic delivery that results in high levels of transfection of the lung, 
kidneys, liver, and spleen. 
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A recent study in our lab demonstrated that utilizing various molecular weights 
of PEG and PEI can produce polyplex structures with vastly different physiochemical 
properties [104].  Parameters such as size, surface charge, and binding stability can be 
controlled by altering PEG and PEI molecular weights and stoichiometry of PEG 
grafting to design vectors mores suitable for gene delivery. Indeed, this project 
demonstrates the versatility of PEG-PEI compounds for designing polyplex structures 
and has important implications for their use as potent non-viral vectors for nucleic acid 
delivery.  
 
Summary and Significance 
 As the era of gene therapeutics for the treatment of DMD reaches its second 
decade we still lack effective treatments to significantly enhance or extend the quality 
of life of patients afflicted with this fatal disease. The overarching significance of this 
project is the implementation of PEG-PEI complexed with ESO’s, provides a realistic 
opportunity to deliver functional levels of dystrophin to skeletal muscle and 
significantly ameliorate pathological symptoms of DMD.  Our emphasis on using PEG-
PEI to produce efficient delivery of the therapeutic compounds has the added 
significance that greater amounts of muscle tissue can be transfected with a more 
clinically feasible mode of delivery.  Thus, the experiments in this project, using mdx 
mice as a model system, will produce significant advances toward the development of 
safe and potent clinical treatments for DMD using gene therapy. 
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Figure 1-4. Mechanism of ESO uptake and delivery. (A) Polyplexes formed from 
cationic co-polymers and ESO maintain a net positive surface which are able to bind 
the cells negatively charged phospholipid bilayer. (B) Membrane bound polyplex 
structures are endocytosed and (C) gathered into early endosomes just below the 
membrane. (D)  Polyplexes are then sorted into low pH late endosomes meant to 
degrade foreign bodies. Free amine groups on PEI act as a proton buffer requiring 
further influx of protons to maintain a pH near 6.0. (E) Contents of late endosomes 
are sorted to lysosomes (orange) where the pH is lowered further and enzymatic 
degradation of proteins takes place. (F) Release from late endosomes and lysosomes 
is thought to be a result of the proton buffering, which causes a higher osmotic 
gradient, resulting in an influx of H20, and eventual rupture of the vesicle. (G) ESO 
dissociates from PEG-PEI where it can be imported to the nucleus and (H) act on it’s 
target pre-mRNA
ESO 
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CHAPTER 2: POLY(ETHYLENE IMINE)-POLYETHYLENE GLYCOL 
COPOLYMERS FACILITATE EFFICIENT DELIVERY OF EXON SKIPPING 
OLIGONUCLEOTIDES TO NUCLEI OF ISOLATED MATURE MUSCLE 
CELLS OF MDX MICE 
 
SUMMARY 
 The objective of this study was to determine the feasibility of PEG-PEI 
copolymers to transfect mature skeletal muscle. In this study we show that cationic 
PEG-PEI copolymers facilitated efficient cellular uptake and nuclear delivery of ESO in 
mature skeletal muscle fibers isolated from mdx mice.  Confocal analysis of dual 
fluorescently tagged PEG-PEI-ESO polyplexes, at 24 h after transfection, showed that 
the copolymer and ESO were co-localized within punctate membrane-associated 
structures. Importantly, ESO was efficiently translocated into myonuclei, while the 
copolymer was mainly excluded from entering the myonuclei.  The morphology of all 
transfected myofibers was perfectly maintained with no signs of damage or cytotoxicty.  
Quantitative confocal analysis showed transfection with PEG-PEI-ESO polyplexes 
resulted in a 6-fold higher uptake of ESO into myonuclei compared with transfections 
of ESO alone. Interestingly, transfections with rhodamine-labeled PEG-PEI copolymers 
yielded approximately a 2-fold higher uptake of ESO into myonuclei compared with 
transfections of unlabeled copolymers.  Attempts to further increase ESO delivery by 
addition of insulin-transferrin-selenium (ITS) to the media, showed no further 
improvement in ESO delivery.  Dose-response analysis indicated saturation of 
endocytotic uptake of the polyplex.  Overall, we conclude that PEG-PEI-ESO 
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polyplexes may prove to be effective and safe agents for induction of dystrophin 
expression and treatment of DMD. 
 
RATIONALE 
 Several excellent reviews have defined the barriers that must be overcome for 
successful delivery of oligonucleotides to target cell nuclei, and have outlined progress 
in carrier-mediated non-viral delivery to overcome those barriers [35, 41, 65, 76, 105-
107]. The difficulties in biopolymer-mediated delivery are further complicated in 
mature skeletal muscle cells, relative to most other cell types, due to their highly-
ordered membrane structure and reduced rate of endocytosis. Surprisingly, there appear 
to be no previous reports that have used PEG-PEI copolymers for delivery of plasmid or 
ESO to striated muscle cells. The experiments in this study establish the feasibility of 
PEG-PEI compounds to facilitate the delivery of ESO’s to myonuclei of mature skeletal 
muscle. 
 The PEG-PEI copolymer in this study is utilizes a high molecular weight PEI 
(25 KDa) polymer with ten 5 KDa PEG chains grafted to the surface 
(PEI25K(PEG5K)10 ). This formulation was selected based on extensive pilot studies 
performed in a variety of cultured cells (data not shown) that demonstrated efficient cell 
membrane association and uptake of fluorescently labeled ESO.    
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MATERIALS AND METHODS 
Polymer Synthesis 
 PEG-PEI polymers were prepared based on a previously reported two-step 
procedure [96]. The specific details of the synthesis of the PEG-PEI polymer, using 
branched poly(ethylene imine)-25000 (PEI25 kDa) and methoxypoly(ethylene glycol)-
5000 (mPEG5 kDa), have been reported elsewhere [104] and are included in Appendix 
B. The physiochemical properties, including size, surface charge and buffering capacity 
were also previously reported by our group [104]. Rhodamine labeling of the 
copolymers is included in Appendix B. 
  
Preparation of PEG-PEI-ESO Polyplexes 
 Preparation of the PEG-PEI-ESO complex is included in Appendix D. All 
experiments in this chapter utilize PEI25K(PEG5K)10 or PEI25Krho(PEG5K)10 to 
formulate the polyplex.  
 
Isolation, Cell Culture, and Transfection of Primary Muscle Fibers 
 Primary muscle fibers are isolated from the flexor digitorum brevus (FDB) 
muscle of the mouse and kept in culture prior to transfection. The protocol for isolating, 
culturing and transfecting primary muscle fibers is included as Appendix E. Mice used 
in this experiment were 9 -12 week old male mdx mice and were euthanized by cervical 
dislocation in accordance with university guidelines. 
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Confocal Imaging and Quantitative Analysis of ESO Uptake Into Myonuclei 
 Muscle fibers were imaged with a Leica TCS SP2 confocal microscope.  For 
qualitative evaluation of cellular uptake of polyplexes, images were obtained with a 40x 
oil immersion objective, and zoom feature of the microscope, at up to 1024x1024 
resolution.  To quantify nuclear uptake of 6-FAM-ESO, images were obtained with a 
40x oil immersion objective at 512x512 resolution, using 2.0 µm intervals per optical 
slice. For each fiber, Z-stacks were obtained from a region that included at least 5 
nuclei.  All images were captured using the same laser intensity and PMT settings.  
Relative ESO uptake was quantified in 5 nuclei per muscle fiber by measuring the mean 
pixel intensity of the 6-FAM signal using NIH ImageJ software. Pixel values measured 
from the 8-bit images ranged from 0 – 255 and are reported as relative light units 
(RLU). For each nucleus, relative ESO level was measured in the optical slice that was 
closest to the midsection of the nucleus, using the Hoechst Dye channel as a guide for 
identifying the boundary.  Prior to processing, all images were background corrected 
using untreated muscle fibers from the same muscle sample as a reference.  A total of 4-
6 muscle fibers from 3 different mice were analyzed for each treatment group. 
 
Statistical Analysis 
 All data are reported as mean values ± SEM.  Statistical differences between 
treatment groups were evaluated by Students t-test (Statview; SAS Institute, Cary, 
USA) as indicated. 
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RESULTS 
 Myofibers isolated from mdx mice were transfected in cell culture with 
polyplexes comprised of 6-FAM-ESO complexed with the rhodamine-labeled 
copolymer PEI25Krho(PEG5K)10.  Confocal analysis at 24 h after transfection showed 
that the copolymer and ESO were co-localized within punctate membrane-associated 
structures that were especially abundant within the perinuclear regions of the myofibers 
(Figure 2-1).  Importantly, the ESO was shown to be efficiently translocated into the 
myonuclei, while the copolymer was almost entirely excluded from entering the 
myonuclei.  These data show translocation of ESO into myonuclei occurred without the 
need for a specific nuclear localization signal.  The polymer-mediated delivery of ESO 
was accomplished without any indication of cytotoxicity.  Indeed, the morphology of all 
transfected myofibers appeared absolutely maintained, as evidenced by the perfectly 
aligned sarcomeric pattern. 
 To determine whether rhodamine conjugated to the copolymer influenced 
transfection efficiency, we also evaluated 6-FAM-ESO uptake following transfections 
with polyplexes comprised of unlabeled PEI25K(PEG5K)10.  Qualitative inspection of 
confocal images indicated that the amount of 6-FAM-ESO translocated to the 
myonuclei after transfection with unlabeled copolymer was less than with the 
rhodamine-labeled copolymer (Figure 2-2). 
 To further evaluate the relative efficiency of ESO delivery to myonuclei we 
developed a quantitative confocal assay whereby the 6-FAM-ESO fluorescence  
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Figure 2-1. Confocal images of a representative FDB skeletal muscle fiber at 24 
h after transfection with polyplex comprised of 6-FAM-ESO (135 µM) 
complexed with the rhodamine-labeled copolymer PEI25Krho(PEG5K)10.  The 
confocal images are from a single optical slice, taken at the approximate mid-
plane of the muscle fiber (paraformalehyde fixed), and are shown at three 
different magnifications.  The confocal images (simultaneous 4-channel 
recordings) included (A-A'') 6-FAM-ESO (green), (B-B'') rhodamine-labeled 
copolymer (red), (C-C'') Hoechst 33342 dye-labeled nuclei (blue), and 
differential interface contrast (DIC).  Panel C-C" shows an overlay the DIC and 
Hoechst images, while panel D-D'' shows a triple overlay of the rhodamine, 6-
FAM and DIC images.  The low and mid magnifications clearly show the 
localization of ESO within all myonuclei in the field of view. The mid and high 
magnification views show that ESO is concentrated within the nuclei (i.e., arrow 
in A'-A''), while the copolymer is almost completely excluded from entering the 
nuclei.  The red-green-DIC overlay demonstrates that copolymer and ESO are co-
localized within punctate membrane-associated structures (yellow structures), 
that are especially abundant in perinuclear regions of the myofiber. 
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Figure 2-2.  Confocal images of representative FDB skeletal muscle fibers at 24 h 
after transfection with polyplexes comprised of 6-FAM-ESO (135 µM) and either (A-
D) rhodamine-labeled copolymer PEI25Krho(PEG5K)10, or (A'-D') unlabeled 
copolymer PEI25K(PEG5K)10. (A''-D'') Control fibers were transfected with 6-FAM-
ESO alone (135 µM).  For each fiber, the confocal images are from an optical slice, 
taken at the approximate mid-plane of the muscle fiber (paraformaldehyde fixed). The 
confocal images show detection of (A-A'') 6-FAM-ESO (green), (B-B'') rhodamine, 
(C'-C'') Hoechst 33342 dye-stained nuclei (blue), and differential interface contrast 
(DIC).  Panel C-C" shows an overlay the DIC and Hoechst images. Panel D-D'' 
shows a triple overlay of the 6-FAM, rhodamine, and DIC images.  Note, although 
there was no rhodamine fluorophore used in fibers shown in A'-D' or A''-D'', the 
output from the rhodamine channel is still shown to indicate the low background and 
minimal autofluorescence in the images.  Transfections with either 
PEI25Krho(PEG5K)10-ESO or PEI25K(PEG5K)10-ESO produced similar levels of 6-
FAM-ESO fluorescence within punctate structures in the perinuclear region.  In 
contrast, nuclear uptake of 6-FAM-ESO was clearly higher for transfections with 
PEI25Krho(PEG5K)10-ESO than unlabeled PEI25K(PEG5K)10-ESO.  Almost no 6-
FAM-ESO was detectable in fibers transfected with ESO alone. 
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intensity was measured within 5 nuclei per muscle fiber (Figure 2-3).  For each 
nucleus, the total 6-FAM fluorescence (relative light units; RLU) was measured in the 
optical slice closest to the midsection of the nucleus.  In all images, the nuclear 
boundary was readily identified in the Hoechst channel, and the ESO uptake was then 
measured within this exact area in the 6-FAM channel. 
 On average, transfection with PEI25Krho(PEG5K)10 in media containing 10% 
FBS produced a 2.2-fold higher ESO uptake into myonuclei than transfections with the 
unlabeled copolymer PEI25K(PEG5K)10 (p = 0.016, Figure 2-4).  However, both the 
rhodamine-labeled and unlabeled copolymers produced a similar level of membrane-
associated punctate structures containing 6-FAM-ESO (Figure 2-2).  Thus, it appears 
that conjugation with rhodamine enhanced polymer-mediated nuclear delivery of ESO 
by increasing translocation across the membrane, not because of increased cell binding 
(see Discussion).  
 PEG-PEI copolymer-mediated delivery of ESO to myonuclei was substantially 
greater than for transfections with ESO alone.  As can clearly be seen in the confocal 
images, transfection with ESO alone resulted in no membrane-associated labeling by 6-
FAM-ESO, and minimal nuclear uptake (Figure 2-2 and Figure 2-3).  Overall, the 
nuclear uptake following transfections with polyplexes containing 
PEI25Krho(PEG5K)10-ESO and PEI25K (PEG5K)10-ESO was 5.5 and 2.8 times greater 
than ESO alone, respectively (Figure 2-4). 
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Figure 2-3.  Method of quantitative confocal analysis of nuclear uptake in 
transfected FDB muscle fibers.  Each row shows five nuclei from an individual fiber 
at 24 h after transfection with either (A) PEI25Krho(PEG5K)10-AO, (B) 
PEI25K(PEG5K)10-ESO, or (C) ESO only.  For each nucleus, images are shown for 
the 6-FAM-ESO (green) and Hoechst 33342 (nuclei stained blue) channels, 
obtained from the optical slice closest to the mid-plane of the nucleus. In all cases, 
the nuclear boundary (white dotted line) was readily identified in the Hoechst 33342 
channel, and the 6-FAM-ESO uptake within this exact area was measured as mean 
pixel value (relative light units; RLU). The histograms below each nucleus show the 
distribution of individual pixel values within the outlined region. 
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Figure 2-4.  Quantitative evaluation of polymer-mediated delivery of ESO to 
myonuclei of mature muscle fibers isolated from mdx mice. Histogram shows the 
level of ESO uptake (relative light units; RLU) in myonuclei at 24 h after 
transfection with polyplexes comprised of 6-FAM-ESO (135 µM) and either the 
rhodamine-labeled copolymer PEI25Krho(PEG5K)10, or the unlabeled copolymer 
PEI25K(PEG5K)10. Control fibers were transfected with 6-FAM-ESO alone (135 
µM).  Transfections were performed in media containing either 10% FBS or 
2%HS+2%ITS.  Nuclear uptake of AO in muscle fibers transfected with 
polyplexes of PEI25Krho(PEG5K)10-ESO and PEI25K(PEG5K)10-ESO was 
significantly greater than for ESO alone in both 10% FBS and 2%Hs+2%ITS 
media (* and ** p < 0.0001).  Nuclear uptake of ESO in muscle fibers transfected 
with PEI25Krho(PEG5K)10-ESO was about 2.2-fold greater than for 
PEI25K(PEG5K)10-ESO in both 10% FBS and 2%Hs+2%ITS media (p = 0.016 
and 0.047, respectively).  There were no significant differences in ESO uptake 
between 10% FBS and 2%HS+2%ITS for any group. All bars indicate mean fiber 
values (± SEM ), based on 5 nuclei per fiber (N values indicated in parentheses). 
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 In an attempt to further increase polymer-mediated ESO delivery to myonuclei, 
the 10% FBS in the culture media was replaced with 2% horse serum (HS) and a 
supplement containing insulin-transferrin-selenium (2%; ITS).  The ITS supplement has 
been previously shown to stimulate endocytosis in muscle [83, 84, 108].  As shown in 
Figure 2-4, the addition of HS and ITS had no significant influence on ESO uptake into 
myonuclei for transfections with polyplexes containing PEI25Krho(PEG5K)10-ESO, 
PEI25K(PEG5K)10-ESO, or ESO alone. 
 The influence of ESO concentration on the magnitude of ESO uptake into 
myonuclei was evaluated following transfection with PEI25Krho(PEG5K)10-ESO 
polyplexes.  Because all transfections were done at a constant ratio of polymer to ESO 
(i.e., N:P = 5), changes in the concentration of ESO and copolymer were equivalent in 
this experiment.  Confocal images revealed a continual increase in the amount of 
membrane-associated polyplex (e.g., co-localized copolymer and ESO) with increasing 
concentrations of ESO (Figure 2-5).  However, the level of ESO uptake into myonuclei 
appeared to be nearly equivalent at the two highest concentrations tested.  
Quantification of the dose-response profile showed a clear plateau in the level of ESO 
uptake into myonuclei at an ESO concentration of about 67.5 µM (Figure 2-6).  The 
plateau was observed for transfections in both 10% FBS and 2% HS-ITS media. The 
plateau in amount of ESO delivered to myonuclei may indicate saturation of cellular 
uptake of the polyplex.  These data further confirm that ESO uptake into myonuclei was 
not influenced by the presence of the ITS supplement. 
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Figure 2-5.  Confocal images 
showing the dose-response 
profile of mdx skeletal muscle 
fibers at 24 h after transfection 
with polyplexes comprised of 6-
FAM-ESO complexed with the 
rhodamine-labeled copolymer 
PEI25Krho(PEG5K)10.  
Transfections were carried out at 
the following concentrations of 6-
FAM-ESO: (A-A') 135 µM, (B-
B') 67.5 µM, (C-C') 33.7 µM, 
and (D-D') 13.5 µM.  For each 
fiber, the confocal images are 
from an optical slice, taken at the 
approximate mid-plane of the 
muscle fiber (paraformaldehyde 
fixed). Shown are overlays of 6-
FAM-ESO and rhodamine (A-D), 
and Hoechst 33342 dye (nuclei) 
and DIC (panels A'-D').  The 
images show a continual increase 
in the amount of membrane-
associated polyplex (e.g., co-
localized copolymer and ESO) 
with increasing concentrations of 
ESO.  In contrast, the level of 
ESO uptake into myonuclei 
appeared to be nearly equivalent 
at the two highest concentrations 
tested. 
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Figure 2-6.  Quantitative evaluation of the dose-response profile of polymer-
mediated delivery of ESO to myonuclei of mature muscle fibers isolated from mdx 
mice. Histogram shows the level of ESO uptake (relative light units; RLU) in 
myonuclei at 24 h after transfection with polyplexes comprised of 6-FAM-ESO and 
the rhodamine-labeled copolymer PEI25Krho(PEG5K)10 in media containing either 
10% FBS or 2%HS+2%ITS.  Control fibers were transfected with 6-FAM-ESO 
alone in 10% FBS.  Nuclear uptake of ESO in muscle fibers transfected with 
polyplexes of PEI25Krho(PEG5K)10-ESO in both 10% FBS and 2%Hs+2%ITS 
increased significantly as ESO concentration was incrementally increased from 13.5 
to 67.5 µM (* and ** p < 0.0001), but showed no further increase as ESO 
concentration was increased from 67.5 to 135 µM (p > 0.05).  Polymer-mediated 
delivery of ESO to myonuclei was significantly higher than for transfections with 
ESO alone at both concentrations tested (p < 0.0001). There were no significant 
differences in ESO uptake between 10% FBS and 2%HS+2%ITS at any ESO 
concentration. All bars indicate mean fiber values (± SEM), based on 5 nuclei per 
fiber (N values indicated in parentheses). 
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DISCUSSION 
 Fully differentiated striated muscle cells present a difficult challenge for non-
viral delivery of nucleotides, due to their post-mitotic status, low rate of endocytosis, 
and highly-ordered membrane structure.  In this report we show that PEG-PEI 
copolymers function as high-capacity, non-toxic nucleotide carriers that facilitate 
efficient delivery of ESO to nuclei of mature myofibers isolated from mdx mice.  
Although, PEG-PEI copolymers have been used for oligonucleotide delivery in other 
cells types [103, 109-115], our findings appear to represent the first documentation of 
PEG-PEI copolymer-mediated delivery of nucleotide (plasmid or ESO) in mature 
striated muscle cells.  Confocal microscopy of muscle cells 24 h after transfection with 
dual fluorescently-labeled PEI25Krho(PEG5K)10-ESO polyplexes revealed that the 
copolymer and ESO were co-localized within membrane-associated punctate structures.  
Inspection of myonuclei in the confocal images, documented that ESO was efficiently 
translocated into myonuclei, while the copolymer was almost entirely excluded from 
entering the nuclei.  Overall, polymer-mediated delivery of ESO was about 5.5-fold 
higher than transfections with ESO alone. 
 The association-dissociation behavior of PEG-PEI-ESO polyplexes is a critical 
aspect that governs their transfection efficiency [35, 41, 65, 76, 105-107].  In this 
system, the electrostatic charge association between cargo and carrier must be strong 
enough to promote cellular uptake, but not too strong as to prohibit release of "free 
ESO", so that ESO can be translocated to myonuclei.  Because ESOs are small and 
contain very few negatively-charged phosphates per molecule (e.g., about 200-fold less 
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than a typical plasmid), it is reasonable to assume that the electrostatic interactions 
between ESO and PEI might be relatively weak.  However, the association-dissociation 
behavior of polyplexes depends on multiple factors including polymer chemistry, ESO 
chemistry, and the environment to which the polyplexes are exposed during transfection 
(i.e., protein concentration, pH).  Therefore, it is difficult to predict a priori, whether a 
particular polyplex formulation will meet the requirements for efficient ESO delivery.  
The dual-fluorescence confocal experiments described herein demonstrate that the 
polyplex formulation chosen for these studies struck a good balance with regards to 
association-dissociation dynamics.  The results indicate that PEI25K(PEG5K)10-ESO 
polyplexes had a strong enough electrostatic charge interaction between the copolymer 
and ESO to facilitate polymer-mediated cellular uptake of ESO, but not too much as to 
prevent release of ESO and translocation of "free ESO" into myonuclei. Although 
previous studies have evaluated PEG-PEI-ESO transfection efficiency in various cell 
types [103, 109-115], to our knowledge this is the first report to use fluorescence-based 
tracking of the association-dissociation behavior of PEG-PEI-ESO polyplexes. 
 Surprisingly, nuclear accumulation of ESO was significantly higher (~2.2 fold) 
for transfections with the rhodamine-labeled copolymer than with the than the unlabeled 
copolymer.  One possible explanation is that because the conjugation of rhodamine to 
the PEI amine groups reduced the number of amines available for binding ESO, the 
ESO was more easily dissociated during transfection.  However, the copolymer was 
conjugated with a minimal amount of rhodamine, such that rhodamine molecules 
occupied only about 2.5% of the total amine groups on PEI25K.  Alternatively, 
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rhodamine may increase the hydrophobicity of the copolymers, possibly resulting in 
more favorable interactions between the polyplexes and the cell membrane.  The higher 
transfection efficiency of rhodamine-conjugated copolymers has implications for 
improved copolymer design.  For example, conjugation of moieties to PEI that have 
similar properties as rhodamine, may lead to increased transfection efficiency, without 
the complications associated with fluorescence. 
 An important aspect to this study was the finding that the polymer-mediated 
delivery of ESO to myonuclei was accomplished without any indication of cytotoxicity.  
The confocal images showed that transfected myofibers maintained perfectly aligned 
sarcomeres, with no visible signs of hypercontraction.  Based on transfection 
experiments with plasmids, it is commonly thought that PEI-based delivery of 
nucleotides is limited by a requisite tradeoff between transfection efficiency and 
cytotoxicity [64, 72, 74, 75, 95, 96].  Due to its high charge density, PEI25K alone (i.e., 
without PEG) is highly cytotoxic.  Charge shielding by PEGylation lowers the 
cytotoxicity of PEI25K, but adding too much PEG may also lower its transfection 
efficiency. We reasoned that PEI25K(PEG5K)10 (e.g., 10 PEG chains per PEI), may 
provide enough charge shielding to reduce cytotoxicity, but still maintain a high enough 
surface charge to promote adequate charge coupling between the polyplex and cell 
membrane.  Indeed, our results using PEI25K-(PEG5K)10-ESO (N:P = 5) show it is 
possible to formulate PEG-PEI-ESO polyplexes that circumvent the potency-
cytotoxcity limitation, and achieve both high transfection efficiency and negligible 
cytotoxicity. 
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 The physiochemical properties of a family of PEG-PEI-ESO polyplexes, 
including the PEI25K(PEG5K)10-ESO polyplex used throughout this report, were 
recently characterized [104]. The size, charge, solubility, and association-dissociation 
properties of polyplexes were each influenced to varying degrees by the particular 
formulation of the copolymer and the stochiometric ratio of copolymer-amines to ESO-
phosphates (i.e., N:P ratio).  In particular, the nature of PEGylation, including Mw of 
PEG and the extent of PEG grafting had a dramatic effect on each of these polyplex 
properties. 
 This detailed physiochemical data was used as a guide in choosing the PEI25K-
(PEG5K)10-copolymer formulation for the present studies.  For example, dynamic light 
scattering measurements of PEI25K(PEG5K)10-ESO polyplexes at N:P = 5, showed that 
their mean hydrodynamic diameter was extremely small (~15 nm).  However, at N:P 
values below 5, the polyplexes formed aggregate particles with much larger diameters 
(~ 150 nm). Because increasing the N:P of PEI-based polyplexes is known to be 
associated with increased cytotoxicity, an N:P of 5 was selected.  Indeed, pilot studies 
confirmed that muscle fibers transfected with PEI25K(PEG5K)10 polyplexes at N:Ps 
less than 5 showed minimal transfection efficiency, while transfections at N:Ps above 5 
were associated with increased cytotoxicity (data not shown).  In addition, zeta potential 
measurements of PEI25K(PEG5K)10-ESO polyplexes showed a net positive surface 
charge of about +8 mV [104].  In contrast, polyplexes formed from PEI25K(PEG5K) 
copolymers with more PEG chains (e.g., 25 or 50 PEGs per PEI) had much lower 
surface charge.  The higher positive surface charge of the polyplex with 10 PEGs per 
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PEI, should promote stronger interactions between the polyplex and negatively-charge 
elements of the muscle cell membrane.  It was also found that polyplexes formed with 
25 and 50 PEGs per PEI25K, were much less stable in a polyanion competition assay, 
indicating that ESO may be too easily dissociated during transfection [104].  Although 
these issues have not been systematically investigated, pilot studies indicated that 
transfection efficiency was substantially lower for polyplexes with 25 and 50 PEGs per 
PEI25K, than the polyplex used in the present study (data not shown). 
 Although the mechanisms of PEI-based nucleotide delivery in muscle cells were 
not specifically addressed, confocal imaging results are consistent with a mechanism 
involving clathrin-mediated endocytosis.  It is generally thought that PEI-nucleotide 
particles migrate along the outer surface of cell membranes, until they become 
associated with clathrin-coated pits, and undergo endocytosis [73, 116].  Clathrin-
mediated endocytosis in muscle cells has been shown to involve the formation of 
endosomal structures and the trafficking of endosomes to the perinuclear region just 
beneath the sarcolemma [108].  Consistent with this view, we observed membrane-
associated punctate structures within the perinuclear region, which contained co-
localized copolymer and ESO.  However, many of the membrane associated structures 
appeared to be significantly larger (600-700 nm) than expected for clathrin-coated 
invaginations which are typically about 150 nm in diameter [87].  Therefore, the 
particles we commonly observed may represent either membrane-associated aggregates 
of polyplex that are still in the process of being endocytosed, or endosomal structures 
composed of fused vesicle-like structures [87].  Given the extremely close association 
  
39
of myonuclei to the sarcolemma, the resolution of our confocal images was not 
adequate to distinguish the precise cellular localization of the polyplexes during 
transfection.  Clearly, higher-resolution techniques such as TEM, and organelle tracking 
techniques will be required to discern these processes in the future. 
 In summary, the results of this study demonstrated the feasibility using PEG-PEI 
copolymers for delivery of ESO to mature skeletal muscle cells. Our rational for 
choosing the specific copolymer formulation proved to be successful in delivering ESO 
with negligible cytotoxicty, showing a dramatic increase in ESO uptake into myonuclei 
of fibers and exclusion of the PEG-PEI copolymers from the nuclei. The increased 
efficiency with the rhodamine labeling provides further insight into possible chemical 
modifications which may improve PEG-PEI copolymer-mediated uptake, such as the 
inclusion of hydrophobic moieties onto the copolymer surface. The results from these in 
vitro studies on the cellular uptake of PEG-PEI-ESO polyplexes serve as a basis for 
further development of non-viral mechanisms of ESO delivery for clinical applications, 
principally for the treatment of DMD. 
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CHAPTER 3: FUNCTIONALIZED PEG-PEI COPOLYMERS COMPLEXED 
TO EXON SKIPPING OLIGONUCLEOTIDES IMPROVE DYSTROPHIN 
EXPRESSION IN MDX MICE 
 
SUMMARY 
ESO’s with 2’-O-methyl modifications are promising drugs for treatment of 
DMD.  However, treatment using these compounds is limited by their poor delivery 
profile to muscle tissue in vivo.  The feasibility of PEG-PEI copolymers as a suitable 
transfection agent for delivery of ESOs to isolated skeletal muscle was described in 
Chapter 2. Our group has also previously established that cationic PEG-PEI copolymers 
enhanced transfection of an ESO that turns on dystrophin expression by skipping the 
mutated exon in dystrophinin skeletal muscle of mdx mice, resulting in widespread 
distribution of dystrophin-positive fibers, but limited dystrophin expression by western 
blots [117]. In the present study, a novel formulation of PEG-PEI, specifically 
PEI2K(PEG5K)10 copolymers, were utilized. PEI2K(PEG5K)10 complexed to 20 mer 
ESO’s which selectively remove the mutated exon 23 of the dystrophin mRNA 
transcript in mdx mice, produced substantially higher levels of dystrophin expression 
following intramuscular injections.  Surface modifications of PEI2K(PEG5K)10  
copolymers with TAT peptide showed the highest level of dystrophin recovery, with a 
6-fold increase in dystrophin-positive fibers compared to ESO alone. The most potent 
TAT-PEI2K(PEG5K)10 -ESO compounds yielded up to 30% of normal dystrophin 
expression by western blot and showed no apparent cytotoxicity.  We conclude that 
TAT-modified PEI2K(PEG5K)10 copolymers are potent, non-toxic, and versatile 
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carriers of ESO’s capable of transfecting skeletal muscle and are promising compounds 
for therapeutic treatment of DMD. 
  
RATIONALE 
 Preliminary experiments using the high molecular weight PEI25K(PEG5K) co-
polymer formulation that was very effective in vitro (Chapter 2) showed very weak 
efficacy when used in vivo. Because of this, our group recently evaluated the 
effectiveness of a family of PEG-PEI copolymers, with varying PEG and PEI molecular 
weights, to deliver 2’OMeAO ESOs to skeletal muscle fibers of mdx mouse limb 
muscles after intramuscular injection of PEG-PEI-ESO polyplexes [117]. When 
effectively introduced to the cell nuclues, the 2’OMeAO ESO’s cause skipping of exon 
23 (which contains a point mutation in mdx mice) in the dystrophin gene during pre-
mRNA splicing, and thus causes recovery of the dystrophin protein.  We showed that 
the best formulation was low molecular weight PEG-PEI copolymer composed of 2 kDa 
branched PEI and 550 Da linear PEG chains.  Single injections of this copolymer, 
complexed to 20 μg ESO’s, demonstrated significantly greater number of dystrophin-
positive fibers compared to other PEG-PEI copolymers containing high molecular 
weight branched 25 kDa PEI [117].  The physiochemical properties of the copolymers 
were explored [104], and showed that low MW PEI 2K-based copolymers had much 
greater polyplex stability and lower overall surface charge than PEI 25K variants, 
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explaining their better in vivo performance.  However, the best copolymers in this study 
yielded less than 5% dystrophin expression by western blot analysis [117]. 
 Presently, we selected a novel formulation of PEG-PEI to evaluate as a potential 
ESO carrier.  This copolymer consists of a branched 2 kDa PEI with ten 5 kDa linear 
PEG chains grafted to the surface ( PEI2K(PEG5K)10 ).  The PEI2K(PEG5K)10-ESO 
polyplexes formed with this copolymer exhibited small size, low surface charge, and 
high stability [104], which we believe may make them more suitable for in vivo delivery 
of ESOs.  To further improve the nanoparticle transfection capabilities and achieve 
higher levels of dystrophin expression, colloidal gold and TAT peptides were 
conjugated to the polymer surface.  Gold nanoparticles have previously been shown to 
enhance biocompatibility [118, 119] and stimulate endocytotic uptake in skeletal 
muscle [108].  Furthermore, the conjugation of gold nanoparticles to PEI has been 
shown to enhance uptake of plasmid DNA in mammalian cells [101].  Arginine-rich 
TAT peptides that make up the protein transduction domain of HIV-TAT have also 
been shown to facilitate nanoparticle uptake in a wide variety of tissues [120, 121].   
 
MATERIAL AND METHODS: 
Polymer synthesis 
PEG-PEI polymers were prepared based on a previously reported two-step 
procedure [96]. The specific details of this PEG-PEI formulation, formulated from PEI2 
kDa and mPEG5 kDa, have been reported elsewhere [104] and are included in Appendix 
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B. The physiochemical properties, including size, surface charge and buffering capacity 
are also reported elsewhere  [104].  
 
Surface functionalization of PEG-PEI nanoparticles 
 Adsorption of colloidal gold to the PEI2K(PEG5K)10 copolymer was performed 
by mixing 300 μl of 5 nm colloidal gold particles (Sigma-Aldrich) with 30 mg of PEG-
PEI (in 1 ml DI H20) and incubating at 4º overnight.  The polymer solution was 
subsequently freeze-dried and stored at -20°C until used.  These colloidal gold adsorbed 
copolymers are designated as CG- PEI2K(PEG5K)10 copolymers.  
 The protocol for covalent attachment of synthetic TAT peptides to the surface of 
PEI2K(PEG5K)10 polymers is described in Appendix C. TAT peptides were coupled to 
PEI2K(PEG5K)10 copolymers at 1:1 or 5:1 peptide to polymer ratio and are referred to 
as TAT-PEI2K(PEG5K)10 and TAT5-PEI2K(PEG5K)10, respectively.  
 
Preparation of PEG-PEI-ESO polyplexes 
 Preparation of the PEI2K(PEG5K)10-ESO complex is included as Appendix D. 
All experiments in this chapter utilize modified or unmodified versions of 
PEI2K(PEG5K)10 to formulate the polyplex  
 
Polyplex Stability: Polyanion Competition Assay 
 The protocol for determining the relative stability of polyplexes formed with 
unmodified and surface modified PEI2K(PEG5K)10 is outlined in Appendix F. 
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Animals 
 All experiments were performed on male mdx mice 6-8 wks of age 
(C57BL/10ScSn-Dmdmdx/J) or age-matched normal male mice (C57BL/10SnJ) 
(Jackson Laboratories, Bar Harbor, ME, USA). 
 
Intramuscular injections 
 The protocol for injecting mdx mice with PEI2K(PEG5K)10-ESO is outlined in 
Appendix G.  Each IM injection contained 15 µl of PEI2K(PEG5K)10-ESO polyplex 
with 5 µg of ESO, or a solution of ESO alone (5 µg in sterile saline).   
 All treated mice received injections on day 0, 3, and 6 and TA muscles were 
harvested 3 weeks after the initial injection.  Each muscle was isolated, pinned to 
parafilm-covered cork, snap frozen in liquid N2-cooled methylbutane, and stored at -80o 
C until further processing.  Control muscles were harvested from uninjected age-
matched mdx and normal mice. 
 
Immunohistochemistry and histology 
 Transverse frozen sections (10 µm) were cut from the belly of each TA muscle 
using a cryostat (Leica CM 3050 S, Bannockburn, IL, USA).  Dystrophin 
immunolabeling was performed on frozen sections as described in Appendix J. 
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Quantification of dystrophin-positive fibers 
 Dystrophin-immunolabeled transverse sections obtained from the midpoint 
along the length of TA muscles were imaged as whole sections using a SPOT RT color 
imaging camera (Diagnostic Instruments, Sterling Heights, MI, USA) mounted on a 
MZFL3 stereomicroscope (Leica).  The number of dystrophin-positive fibers in entire 
muscle cross-sections were counted using the cell counter function of ImageJ software 
(rsb.info.nih.gov/ij/plugins/cell-counter.html). 
 
Western Analysis 
 Thick sections of frozen TA muscles (60 μm) immediately adjacent to the thin 
sections used for immunolabeling were excised for western analysis.  Protein extraction 
was performed as described in Appendix H.  Quantification of the dystrophin protein 
was performed on extracted samples by western analysis as described in Appendix J.  
 
Statistical Analysis 
 All data are reported as mean values ± SEM.  Statistical differences between 
treatment groups were evaluated by ANOVA (Statview; SAS Institute, Cary, NC). 
 
RESULTS 
 The goal of this study was to evaluate the relative efficacy of a family of PEG-
PEI copolymers complexed with ESOs for their ability to produce dystrophin 
expression in skeletal muscle fibers of mdx mice after intramuscular injections.  A 
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specific formulation of PEG-PEI copolymer was selected based on its advantageous 
macromolecular properties including tiny size (~ 10 nm), low surface charge, and high 
ESO binding stability [104].  Various surface modifications were made to this 
copolymer to improve the transfection properties.  The copolymer formulations used in 
this study are schematized in Figure 3-1.  To determine if any of the surface 
modifications affected the polyplex stability, a polyanion competition assay was utilized 
(Figure 3-2).  The addition of TAT peptides to the surface of the copolymer had no 
significant effect on polyplex stability.  However, the adsorption of colloidal gold 
nanoparticles to PEI2K(PEG5K)10 did markedly reduce the stability of the resultant 
polyplexes.  The IC50 values calculated from the stability curves showed that both 
formulations with colloidal gold were significantly less stable than unmodified 
PEI2K(PEG5K)10  and TAT5- PEI2K(PEG5K)10  (P < 0.05). 
 Tibialis anterior (TA) muscles were injected on day 0, 3 and 6 with 5 μg of ESO 
complexed to PEI2K(PEG5K)10 copolymers and were evaluated for dystrophin levels 
three weeks after the first injection.  Transverse sections obtained from the mid-portion 
of TA muscles were labeled with a dystrophin antibody and evaluated for dystrophin 
expression.  Muscles treated with the PEI2K(PEG5K)10-ESO polyplex showed a 
substantial improvement in dystrophin expression compared with muscles treated with 
ESO alone (Figure 3-3).  Hemotoxylin & eosin staining revealed no signs of 
inflammation, tissue remodeling, or other signs of cytotoxicity compared to untreated 
mdx tissue (Figure 3-3), confirming that these PEI2K(PEG5K)10 copolymers were not  
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Figure 3-1. Schematic of PEI2K(PEG5K)10–ESO formulations used in this 
study including:(A) unmodified PEI2K(PEG5K)10, (B) colloidal gold 
adsorbed to PEG-PEI (CG-PEI2K(PEG5K)10), (C) PEI2K(PEG5K)10 
modified by TAT peptide at a 1:1 peptide:polymer molar ratio (TAT- 
PEI2K(PEG5K)10), (D) PEI2K(PEG5K)10 modified by TAT peptide at a 
5:1 peptide:polymer molar ratio (TAT5-PEI2K(PEG5K)10), and (E) 
Colloidal gold adsorbed to TAT5-PEI2K(PEG5K)10 (CG-TAT5-
PEI2K(PEG5K)10 ). 
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Figure 3-2.  Polyplex stability evaluated with a heparin competition assay.  (A) 
Destabilization of PEI2K(PEG5K)10-ESO polyplexes formulated at N:P = 5 with 1 
μg of ESO was accomplished by exposure to increasing amounts of heparin.  The 
samples were run on agarose gels, and the amount of ESO released from the 
copolymer was quantified with densitometry by normalizing against the intensity of 
the band from a sample containing ESO alone on the same gel.  Samples from each 
group were repeated in triplicate.  (B) Heparin concentration required to release 50% 
of ESO from each polyplex (IC50) from data shown in panel A.  IC50 values of 
unmodified PEI2K(PEG5K)10 and TAT5- PEI2K(PEG5K)10 are both significantly 
higher than CG- PEI2K(PEG5K)10 and CG-TAT5- PEI2K(PEG5K)10 (*P < 0.05).  
No statistical difference was found between unmodified PEI2K(PEG5K)10 and 
TAT5-PEI2K(PEG5K)10 (P = 0.52). 
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cytotoxic, as has been shown with other formulations of PEG-PEI tested in skeletal 
muscle [117]. Immunolabeling for dystrophin following treatments with the various 
functionalized derivatives of PEI2K(PEG5K)10-ESO revealed denser areas of 
dystrophin-positive fibers than for the unconjugated copolymer (Figure 3-4).  Muscles 
injected with the unmodified PEI2K(PEG5K)10-ESO averaged 368 (± 79) dystrophin-
positive fibers, which was about 8-fold more than ESO alone (Figure 3-5).   Addition 
of colloidal gold to this copolymer (CG- PEI2K(PEG5K)10) increased the number of 
dystrophin-positive fibers to 520 (± 63), but the increase was not statistically better than 
the PEI2K(PEG5K)10 formulation (P = 0.18). 
Conjugation of TAT to PEI2K(PEG5K)10 greatly increased the number of 
dystrophin positive fibers, with TAT-PEI2K(PEG5K)10, TAT5-PEI2K(PEG5K)10, and 
CG-TAT5-PEI2K(PEG5K)10 copolymers producing 655 (± 143), 642 (± 34), and 804 (± 
185) dystrophin-positive fibers, respectively (Figs. 3-4 and 3-5).   Each of the TAT-
conjugated derivatives produced statistically greater numbers of dystrophin-positive 
fibers compared to the PEI2K(PEG5K)10 formulations, with the best of the formulations 
(CG-TAT5- PEI2K(PEG5K)10) generating a 2.3-fold increase over the 
PEI2K(PEG5K)10 copolymer.  The total number of fibers in TA muscles was estimated 
at about 2000 [25, 122], indicating that approximately 40% of the muscle fibers were 
transfected under the best conditions. 
 The effectiveness of all copolymers was quantitatively evaluated using western 
analysis (Figure 3-6).  The unmodified PEI2K(PEG5K)10-ESO polyplex produced an 
average of 13.8 ± 1.0 % of normal levels of dystrophin (Figure 3-7), which is higher  
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Figure 3-3. Dystrophin induction in TA muscles of mdx mice 3 weeks after 
intramuscular injections of ESO alone and ESO complexed with PEG-PEI 
copolymers.  Images show dystrophin immunolabeling of TA muscle cross-sections 
(4X and 10X magnifications) and H&E staining (10X) of serial sections as follows: (a-
a”) normal, (b-b”) mdx untreated, (c-c”) mdx injected with ESO alone, and (d-d”) mdx 
injected with PEG-PEI–ESO polyplex. 
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Figure 3-4.  Number of dystrophin-positive fibers in TA muscles of mdx mice at 3 
weeks after intramuscular injections of either 15 µg of ESO alone, or polyplexes of 
PEI2K(PEG5K)10–ESO, CG- PEI2K(PEG5K)10–ESO, TAT- PEI2K(PEG5K)10–
ESO, TAT5- PEI2K(PEG5K)10–ESO, and CG-TAT5- PEI2K(PEG5K)10–ESO.  
Results are also shown for untreated mdx muscles which are known to contain a 
small number of revertant fibers.  Muscles injected with the 3 different TAT-
modified formulations showed a significantly higher number of dystrophin-positive 
fibers compared to unmodified PEI2K(PEG5K)10-ESO (ANOVA; *P <0.05).  
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Figure 3-5.  Number of dystrophin-positive fibers in TA muscles of mdx mice at 3 
weeks after intramuscular injections of either 15 µg of ESO alone, or polyplexes of 
PEI2k(PEG5K)–ESO, CG-PEG-PEI–ESO, TAT- PEG-PEI–ESO, TAT5-PEG-PEI–
ESO, and CG-TAT5-PEG-PEI–ESO.  Results are also shown for untreated mdx 
muscles which are known to contain a small number of revertant fibers.  Muscles 
injected with the 3 different TAT-modified formulations showed a significantly higher 
number of dystrophin-positive fibers compared to unmodified PEG-PEI-ESO 
(ANOVA; *P <0.05).  
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Figure 3-6. Western analysis of dystrophin expression in TA muscles of mdx 
mice at 3 weeks after intramuscular injections of ESO complexed with 
unmodified and modified PEI2K(PEG5K)10 copolymers. Samples were 
obtained from age-matched normal (lane 1), mdx untreated (lane 2), ESO alone 
(lane 3), PEI2K(PEG5K)10-ESO (lane 4), CG- PEI2K(PEG5K)10-ESO (lane 5), 
TAT- PEI2K(PEG5K)10-ESO (lane 6), TAT5- PEI2K(PEG5K)10-ESO (lane 7), 
and CG-TAT5- PEI2K(PEG5K)10-ESO (lane 8).  For the injected muscles, 60 
μm sections were cut directly adjacent to the block used for 
immunohistochemical analysis. All samples contained equal amounts of total 
protein. 
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Figure 3-7. Summary of western analysis of dystrophin expression in mdx mice 3 
weeks after intramuscular injections of PEG-PEI-ESO polyplexes. 
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Figure 3-8. Dystrophin expression in TA muscles of mdx mice after three 
intramuscular injections of 5 μg ESO complexed with TAT5-PEI2K 
(PEG5K)10 copolymer.  Dystrophin immunolabeling of a whole TA transverse 
section obtained from the midpoint along the length of the muscle.  
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than previously reported amounts for other PEG-PEI formulations [117].  As was the 
case for the dystrophin-positive fiber counts, western blot analysis of muscles treated 
with the TAT-conjugated derivatives produced significant increases in dystrophin 
expression compared to the other formulations.  Specifically, the muscles injected with 
TAT- PEI2K(PEG5K)10, TAT5- PEI2K(PEG5K)10, and CG-TAT5- PEI2K(PEG5K)10 
copolymers averaged 22.3 (± 3.0), 27.9 (± 4.2), and 29.2 (± 3.6) of the dystrophin 
expression in normal muscle (Figure 3-7).  As a group, the TAT derivatives showed 
around a 2-fold increase in dystrophin expression compared to the unconjugated 
PEI2K(PEG5K)10 copolymer. 
The distribution of dystrophin-positive fibers is clearly demonstrated in images 
from whole muscle transverse sections (Figure 3-8).  Large areas of dystrophin positive 
fibers can be seen throughout the muscle sections, especially in the center regions of the 
muscle.  Areas near the periphery of the muscle show significantly less or no 
dystrophin-positive fibers, presumably due to the inability of the polymer to disperse 
fully and uniformly throughout the muscle tissue. 
 
DISCUSSION 
 The goal of this study was to evaluate the capacity of novel functionalized 
derivatives of PEI2K(PEG5K)10 copolymers to improve delivery of ESOs to skeletal 
muscle fibers of mdx mice.  We chose to use a PEG-PEI copolymer that was previously 
shown in solution studies to have potentially favorable macromolecular properties for 
oligonucleotide delivery including small size, low surface charge, and high binding 
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affinity to synthetic 2’OMeAO’s [104], but had not previously been tested in vivo.  We 
showed that this copolymer and several functionalized derivatives produced much 
higher levels of dystrophin in mdx limb muscles than ESO alone at 3 weeks after the 
first intramuscular injection. The level of dystrophin recovery ranged from 15-30% of 
normal levels, and was accomplished while utilizing a low amount of ESO (15 μg total).  
The 30% dystrophin recovery in the present study is better than the highest level of 
dystrophin expression reported from pluronic F127 complexed to 2’MeO ESO, which 
showed about 20% dystrophin recovery at 4 weeks after a single intramuscular injection 
of 5 μg ESO, although this was not systematically investigated [122]. The 30% 
dystrophin expression herein also exceeds that reported using other PEG-PEI 
copolymers [117]. 
 The high level of dystrophin expression achieved in the present study was 
accomplished with PEI2K(PEG5K)10 carriers that did not appear to elicit any overt 
signs of cytotoxicity.  These data are in contrast to previous reports that suggested that 
PEI-based carriers are inherently cytotoxic [44].  We believe that the combination of a 
low MW PEI with high MW PEG provided a favorable formulation which was both 
effective and non-toxic. 
Recent reports have focused on oligonucleotide analogues such as PMO or PNA 
as alternatives to 2OMeAO’s, suggesting the uncharged backbones result in superior 
stability and lack the necessity of a carrier [25, 45-51]. Up to 60% dystrophin 
expression was recently reported in TA muscles of mdx mice after intramuscular 
injections of 10 µg PMO [46], although these results were only an estimate and did not 
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include systematic quantitative analysis of either fiber counts or western blots in the IM 
injected muscles.  Although it seems clear that PMOs with no carrier are better than 
naked 2’OMeA oligonucleotides for in vivo targeting of skeletal muscle, the 
PEI2K(PEG5K)10 carriers developed herein overcome this limitation to some extent.  
The 15-30% level of dystrophin expression in the present study is about 3-5 fold 
greater than we previously reported with a different PEG-PEI formulation that 
contained low MW PEI2K and low MW PEG [117].  Interestingly, fiber counts 
revealed roughly the same number of dystrophin-positive fibers in both studies.  This 
seems to indicate that there is more dystrophin being produced in each dystrophin-
positive fiber in the present study.  A likely explanation for this is that the 
PEI2K(PEG5K)10 copolymer used herein exhibits the highest binding affinity to ESO 
compared with other PEG-PEI formulations that have been tested [104], and the 
conjugated TAT epitopes add further potency.  However, part of the significant 
improvement in dystrophin expression may be attributed to the use of a triple injection 
regimen of smaller doses compared to that done previously (858Williams et al). 
 In an effort to stimulate uptake of the injected polyplexes, colloidal gold and 
TAT peptides were conjugated to the PEI2K(PEG5K)10 nanoparticles.  Covalently 
linking TAT peptides to PEI2K(PEG5K)10 showed a significantly higher number of 
dystrophin positive fibers as well as overall level of dystrophin expression.  In the case 
of TAT5- PEI2K(PEG5K)10, the overall level of dystrophin recovery was double that of 
the unmodified nanoparticles. The addition of colloidal gold did not have a significant 
effect on the levels of dystrophin recovery for either unmodified or TAT-modified 
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PEI2K(PEG5K)10 treatments as measured by fiber counts and western analysis of 
dystrophin levels.  One possible explanation for this is that the copolymers and gold 
particles relied on electrostatic interactions, rather than covalent binding.  The 
electrostatic association of colloidal gold adsorbed to nanoparticles was not studied, and 
could potentially be short-lived when introduced in vivo, thus having only a minor 
effect if any.  A stronger linkage between gold particles and PEI2K(PEG5K)10 
nanoparticles may prove to be more efficient, as demonstrated by Thomas et al [101].  
Interestingly, we found the gold nanoparticles significantly destabilized the polyplex, 
diminishing any benefits that they might provide in enhancing uptake (Figure 3-2), an 
observation that was not seen in the TAT-modified PEI2K(PEG5K)10 group. 
 While the smaller size and lower charge of PEI2K(PEG5K)10 polymers 
combined with triple injections of smaller doses of ESO showed significant 
improvement in distribution of ESO through muscle, still roughly 50% of the cross-
sectioned muscle lacks evidence of dystrophin recovery (Figure 3-8).  The inherent 
cationic nature of these copolymers may still cause significant interaction between 
PEI2K(PEG5K)10-ESO nanoparticulates and components of the extracellular space, 
restricting diffusion throughout the muscle.  We have shown in this report, and previous 
work [117], that slight modifications to the nanoparticle structure can provide marked 
increases in their transfection capabilities.  Further modifications of PEI2K(PEG5K)10 
carriers may produce still higher levels of dystrophin expression and provide suitable 
protection for oligonucleotides, greatly improving their functionality for use in vivo. 
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CHAPTER 4:  FORMULATION OF POLYLACTIDE-CO-GLYCOLIC ACID 
NANOSPHERES FOR THE ENCAPSULATION OF POLY(ETHYLENE 
IMINE)-POLY(ETHYLENE GLYCOL) COPOLYMERS COMPLEXED TO 
EXON SKIPPING ANTISENSE OLIGONUCLEOTIDES  
 
 
SUMMARY 
 
 This study examines the feasibility of encapsulating cationic PEG-PEI-ESO 
polyplexes into biocompatible and biodegradable PLGA nanospheres. A modified 
double emulsion procedure was developed, which after a systematic study of the 
formulation parameters, successfully encapsulated PEG-PEI-ESO structures within 
small PLGA nanospheres with average diameters less than 300 nm. Surface charge 
analysis confirmed that the cationic charge of the polymer was effectively shielded 
within the nanospheres. Interestingly, measurements of encapsulated ESO showed the 
PEG-PEI copolymers increased the encapsulation efficiency of ESO’s from 60% to 
almost 100% in certain PLGA formulations. Slow overall release of the ESO from the 
nanospheres was observed over the course of 21 days with release of ESO reaching only 
60% using the fastest degrading PLGA. Overall, the feasibility of encapsulating PEG-
PEI-ESO compounds into nanospheres to mask the cationic surface charge was 
successfully confirmed. Qualitative studies using rhodamine labeled PEG-PEI polymers 
showed improved distribution of the polyplex through muscle tissue. We conclude that 
the compounds developed could potentially be utilized to deliver cationic polyplexes to 
dystrophic skeletal muscle in vivo for long term sustained release of ESO that could be 
used to treat DMD.  
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RATIONALE 
 Cationic PEI based transfection agents have repeatedly been demonstrated to be 
one of the most effective non-viral vectors for facilitating ESO uptake in vitro due to a 
so called “proton sponge” effect. When utilized in vivo, however, the effectiveness of 
cationic polyplexes may be limited by non-specific binding to proteins and other 
components in the extracellular environment. Surface modifications using inert PEG 
can dramatically reduce non-specific binding but at the cost of destabilizing the 
interaction with ESO’s. This tradeoff is a major obstacle in developing more effective 
PEG-PEI compounds.  Although recent progress using cationic PEG-PEI copolymers 
demonstrated significant improvement in delivery of ESO’s in vivo by altering the 
surface properties and polyplex stability [117] (Chapter 3), these cationic polyplexes 
are still limited in their ability to transverse through a protein rich extracellular 
environment when injected in vivo (Chapter 3). In order to overcome these limitations, 
methods of shielding the cationic surface charge of the polyplex must be further 
explored.   
 Biodegradable poly(lactic-co-glycolic acid) (PLGA) polymers are versatile and 
biocompatible compounds that have been FDA approved and utilized in a wide variety 
of drug delivery applications [123, 123, 124], including the encapsulation of nucleic 
acids.  PLGA nanospheres properties can be controlled by utilizing a wide variety of 
available PLGA chemistries and altering the synthesis conditions, providing vesicles 
with a broad size range and variable release kinetics [125]. PLGA nanospheres have 
been used for the encapsulation of plasmid DNA and AO’s [126, 127] for various 
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treatments without the use of PEG-PEI or other cationic carriers. Several groups have 
incorporated PEI into PLGA formulations to produce cationic nanospheres for 
intranasal delivery to pulmonary epithelial cells [128], oral delivery as an 
immunostimulant [129], or simply to improve in vitro transfection efficiencies [130] 
[131] . A few groups have performed encapsulation of carrier-nucleic acid polyplexes 
using PEI or polylysine, however this work is restricted to micron sized vesicles [12, 
132-136] and is unsuitable for systemic or intramuscular delivery. To date, no group has 
demonstrated encapsulation of a cationic polyplex into a PLGA nanospheres suitable 
for in vivo use.  
.  
Materials and Methods 
Polymer synthesis 
 The specific details of the synthesis of the PEG-PEI polymer have been reported 
elsewhere [104] and are included in Appendix B. All experiments in this chapter use 
PEI25K(PEG5K)10 or PEI25Krho(PEG5K)10., exactly as described in Chapter 2. 
 
Synthesis of PLGA nanospheres encapsulated with PEG-PEI-AO polyplexes 
 Encapsulation of the PEI25K(PEG5K)10-ESO into PLGA nanospheres was 
performed using a double emulsification (water-in-oil-in water) technique outlined in 
Appendix K (only final formulation parameters are given). Experiments used ester 
endcapped PLGA (50:50) MW 72 kDa unless otherwise indicated. 
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Particle size and surface charge 
 Particle size and surface charge were measured using Zetasizer (Malvern, 
Southborough, MA, USA). Nanospheres were suspended in diluted 1X PBS (1:800 in 
DI water) at a 0.1 mg/ml concentration and loaded into a disposable zeta potential cell 
(Malvern) for both size and surface charge measurements.  
 
Encapsulation efficiency 
 The amount of oligonucleotide encapsulated by the nanospheres was determined 
by spectrophotometry.  Lyophilized sample (1 mg) was dissolved in 500 μl 0.5 M 
NaOH, centrifuged for 30 minutes at 16g (Eppindorf 5415D,Westbury , NY USA), and 
the absorbance of supernatant measured by spectraphotometry (Ultraspec 2100; 
Amersham Biosciences, Piscataway, NJ, USA) at a 260 nm wavelength using a low 
volume quartz cuvette. The concentration of ESO in the sample was determined by a 
standard curve made using unencapsulated ESO at varying concentrations dissolved in 
0.5 M NaOH. Loading efficiencies are reported from a sample size of n =3.   
 
Release kinetics 
 Samples of 0.5 mg nanospheres suspended in 1X sterile PBS pH 7.2 (1 mg/ml) 
were made for each desired time point. Each sample was sealed and placed in a 
rotisserie hybridization oven (Problot 6; Labnet, Edison , NJ) and incubated at 37º. At 
the desired time points, the sample was removed from the oven and centrifuged for 30 
minutes at 16g. The supernatant was discarded and the remaining pellet was dissolved 
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in 0.5 M NaOH  Samples for each time point were evaluated by a UV absorbance in 
exactly the same manner as the encapsulation efficiency. 
 
Animals 
 All experiments were performed on male mdx mice 6-8 wks of age 
(C57BL/10ScSn-Dmdmdx/J) or age-matched normal male mice (C57BL/10SnJ) 
(Jackson Laboratories, Bar Harbor, ME, USA). 
 
Intramuscular injections 
 The protocol for injecting mdx mice with PEI25K(PEG5K)10-ESO is outlined in 
Appendix G.  Each IM injection contained 15 µl of PLGA encapsulated or 
unencapsulated PEG-PEI-ESO polyplex with 5 µg of ESO.   
 All treated mice received single injections in the TA muscles and were harvested 
24 Hhours after the initial injection.  Each muscle was isolated, pinned to parafilm-
covered cork, snap frozen in liquid N2-cooled methylbutane, and stored at -80o C until 
further processing.  Control muscles were harvested from uninjected age-matched mdx 
and normal mice. 
 
Results 
The goal of this study was to evaluate the possibility of encapsulating PEG-PEI-
ESO polyplexes within biodegradable PLGA nanospheres for the purpose of improving 
delivery of cationic polyplexes in vivo. The main parameters that are investigated in this 
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study are the effects of sonication amplitude, PVA concentration, and PLGA structure. 
These parameters are critical in determining the resulting properties of nanospheres as 
well as encapsulation efficiency and release kinetics of PEG-PEI-ESO polyplexes.  
 The initial method of formulation used in this study was a double emulsion 
procedure adapted from a protocol outlined by Cohen-Sacks et al [137] and is 
schematized in Figure 4-1.  The study by Cohen-Sacks reported that unloaded 
nanospheres, or nanospheres loaded with a 20mer phosphothioated ESO, showed 
diameters of roughly 300 nm in size. Nanospheres formulated in these experiments used 
the same procedure to encapsulate either PEI25K(PEG5K)10-ESO polyplex, ESO alone, 
or just water (unloaded). The initial results showed ESO loaded or unloaded 
nanospheres were nearly the same size 292.5 ±3.1 and 294.9 ± 2.4 nm respectively 
(Figure 4-2A). Nanospheres that were loaded with PEI25K(PEG5K)10-ESO polyplexes 
showed a higher mean diameter (345.4 ± 28.4 nm) which was statistically significant 
compared to unloaded nanospheres (P = .0079). Additionally, larger insoluble 
aggregates were apparent that were not seen in samples prepared without 
PEI25K(PEG5K)10 polymers present.  Experiments were repeated in triplicate (n=3) on 
independently prepared samples for each group.   
 For each of these samples, the average yield and encapsulation efficiency (EE) 
of ESO was calculated (Figures 4-2B and 4-2C). The yield for polyplex loaded, ESO 
loaded, or unloaded nanospheres was roughly the same (71.0 ± 10.5% , 68.5 ±  10.8%, 
and 64.5 ± 15.10% respectively). The percentage yield was calculated based on the 
initial mass of PLGA used plus the mass of the encapsulated compound. The EE of the
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Figure 4-1. Overview of Nanospheres formulation. This figure describes the 
principal of nanosphere formulation and PEI25K(PEG5K)-ESO encapsulation using 
a double emulsion (water in oil in water) technique.   
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Figure 4-2. Characterization of nanospheres synthesized by double emulsion 
method. (A) The mean diameters are shown for nanospheres containing 
PEI25K(PEG5K)10-ESO polyplex formulated at an N:P ratio of 5 using 1 mg 
ESO, nanospheres containing only 1 mg of ESO, and unloaded nanospheres. (B) 
Polymer yields are shown for the same samples, calculated based on the weight 
of the resulting nanospheres and initial mass of PLGA used. (C) The resulting 
encapsulation efficiencies (EE) for ESO are shown for the same samples 
calculated based on the theoretical maximum possible amount of ESO per 
milligram PLGA. Each group is an average of three separate samples (N=3) 
Nanospheres loaded with the polyplex show a statistically higher average 
diameter compared to unloaded and ESO alone loaded samples (*P = 0.0079). 
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polyplex loaded and ESO loaded nanospheres were 55.1 ± 14.4% and 64.1 ± 21.3% 
respectively. Unloaded nanospheres used as controls resulted in 3.8 ± 3.4%  EE 
possibly due to a low level of absorbance of the dissolved PLGA polymers that may 
cause error when quantifying the DNA using UV spectraphotometry. 
 To achieve a smaller mean particle sizes and eliminate aggregate formation, 
pilot studies were performed by altering the formulation parameters, namely the 
sonication amplitude and the PVA concentration (Figure 4-3). Unloaded nanospheres 
were formulated using a 2% PVA (w/v) solution while the sonication amplitude was 
increased from 38 Watts (roughly 75% of the maximum sonication amplitude) to 51 
Watts (maximum sonication amplitude). Nanospheres formed at 38 W had a mean 
diameter of 316.6 nm (slightly higher that shown in figure 2A) while nanospheres 
formed at 51 W had a mean diameter of 264.3 nm, slightly more than 50 nm smaller in 
diameter (Figure 4-3A). The effect of PVA concentration was tested with PVA 
concentrations ranging from 2% -10% (w/v) using a sonication amplitude of 51W. The 
resulting diameters showed a noticeable trend of decreasing diameter size with 
increasing PVA concentration (Figure 4-3B). The smallest diameter sizes of 233.0 nm 
were seen with a PVA concentration of 8% (w/v), but were not much smaller than 5% 
or 10% concentrations (235.7 and 238.6 nm respectively). The mass yield was 
noticeably lower at PVA concentrations of 8% and 10% (55.0% and 52.1% 
respectively) (Figure 4-3C), so a 5% (w/v) PVA concentration was selected as the 
optimal amount and used for subsequent experiments. 
  
70
 
Figure 4-3.  Pilot study on the effect of sonication amplitude and PVA 
concentrations on the size and yield of unloaded nanospheres. (A) The effect of 38 
W sonication (roughly 80% of the maximum amplitude) and 51 W sonication 
(maximum amplitude) on the resulting nanosphere size are shown. The samples in 
this experiment were formulating using 2% (w/v) PVA in the secondary aqueous 
phase (B) The effect of PVA concentration on nanosphere size is shown here for 
2%, 3%, 5%, 8%, and 10% PVA (w/v) formulated using 51 W sonication. (C) The 
polymer yield for the same samples shown in figure 3B are shown here. All results 
(A-C) are reported from single samples (n =1) and were not repeated. 
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 The formulation with increased PVA concentration and higher sonication 
amplitude produced significantly smaller sized nanospheres. However, the overall  
polydispersity of the samples remained high, indicating a high degree of non-uniformity 
in terms of nanosphere size. To achieve a more homogenous sonication, the procedure 
was changed so that the secondary aqueous phase was distributed into 3 smaller 
scintillation vials and sonicated individually at a lower volume. The samples were then 
recombined. This procedure resulted in drastically lower mean diameters (154.8 ± 16.4 
nm) (Figure 4-4A) (n = 3) and noticeably lower polydispersities in unloaded 
nanospheres (Figure 4-4B). The lower volume and higher amplitude sonication was 
subsequently used for all proceeding experiments. 
 Pilot studies were also performed using PEG-PEI-AO polyplexes at varying 
quantities. PEI25K(PEG5K)10-ESO complexes were formulated at an N:P ratio of 5 
using 1 mg, 0.5 mg, 0.25 mg, or 0 mg ESO (unloaded) in the primary aqueous phase. 
Figure 4-5A shows a linear trend in nanosphere size with decreasing amounts of ESO 
(and correspondingly decreasing amounts of PEI25K(PEG5K)10 co-polymer). No trend 
in encapsulation efficiency with varying polyplex quantities was observed Figure 4-5B.  
Despite the smaller size of nanospheres loaded with less polyplex, 1 mg ESO quantities 
were used for subsequent experiments. 
 Nanospheres were formulated using lower molecular weight (50 kDa) non-end 
capped polymers and compared with nanospheres formulated used in the previous 
experiments. All nanospheres were formulated using %5 (w/v) PVA concentrations 
with a 51 Watt low volume sonication. PEG-PEI-AO polyplexes were formulated at an 
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Figure 4-4. The effect of sonication amplitude and volume on unloaded 
nanosphere size and polydispersity. To achieve more homogeneity in resulting 
PLGA nanosphere samples, the secondary aqueous phase was split into three 
smaller volumes in scintillation vials prior to the second sonication step. (A) The 
difference in the sonication amplitude and volume on the resulting nanosphere 
size is shown using a sonication amplitudes of 38 and 51 W and 5% (w/v) PVA 
with a high volume an amplitude of 51 W with a low volume. Average values are 
from three separate samples (N = 3) (B) A single sample from each group in 
Figure 4-4A is shown here to demonstrate a smaller mean size and lower 
polydispersity of nanospheres when using a lower sonication volume and higher 
amplitude. 
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Figure 4-5. Pilot study on the effect of PEG-PEI-ESO amount on nanosphere 
size and encapsulation efficiency. (A) The diameter of nanospheres loaded with 
PEI25K(PEG5K)10-ESO polyplexes using 1 mg ESO, 0.5 mg ESO, 0.25 mg 
ESO, and 0 mg ESO. (B) The encapsualation efficiency of the ESO of the same 
samples. 
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 N:P ratio of 5 using 1 mg of ESO. Figure 4-6A shows the resulting sizes of unloaded 
and polyplex loaded nanospheres using 72 kDa, 50 kDa, and 17 kDa molecular weight 
PLGA polymers. Unloaded nanospheres showed mean sizes of 154.8 ± 16.4, 162.5 ± 
19.5, and 160.1 nm for 72 kDa, 50 kDa, and 17 kDa PLGA polymers respectively. 
Polyplex loaded nanospheres showed mean sizes 206.9 ± 42.9, 241.7 ± 18.7 and 255 nm 
for 72 kDa, 50 kDa, and 17 kDa PLGA respectively.  No difference in the sizes between 
the different PLGA polymers was observed for either loaded or unloaded nanospheres. 
Figure 4-6B shows the overall surface charge for the same samples as in Figure 4-6A. 
Suprisingly, unloaded nanospheres formulated using laurel ester end capped 72 kDa 
PLGA showed only a slightly more neutral surface charge (-17.0 ± 1.4 mV) compared 
to non end-capped 50 kDa PLGA (-19.8 ± 1.2 mV) and non end-capped 17 kDa PLGA 
(-24.4 mv) in the unloaded samples. However, nanospheres loaded with polyplex 
showed significantly less surface charge for 72 kDa PLGA (-12.0 ± 0.8 mv) compared 
to 50 kDa PLGA (-20.1 ± 1.0 mV) and 17 kDa PLGA (-22.8 mV). No noticeable 
difference in surface charge was seen between unloaded and loaded nanospheres for 50 
kDa and 17 kDa PLGA samples.  The results for the surface charge measurements are  
rather suprising, and possible explanations are further mentioned in the discussion 
section. Encapsulation efficiency for the loaded nanospheres is shown in Figure 4-6C. 
The EE for 72 kDa PLGA was significantly less (57.6 ± 7.6%) compared to both 50 
kDa PLGA (103.8 ± 7.8%) and 17 kDa PLGA (90.0%). Potential reasons for the 
pronounced increase in EE are given in the discussion section. The overall yield of the 
polymer is also shown in Figure 4-6D, showing the overall polymer yield to be 
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Figure 4-6. Properties of nanospheres formulated using three different PLGA 
polymers. PLGA(50:50) at molecular weights of 72 kDa (blue) , 50 kDa (gray), and 
17 kDa (green), were used to encapsulate ESO. The high molecular weigh (72 kDa) 
polymer also contained a laurel ester end group instead of a carboxylic acid. (A) The 
average size of the unloaded polymers and PEG-PEI-AO loaded polymers are shown. 
No statistical difference between the PLGA polymers was observed for either loaded 
or unloaded nanospheres (P>0.05). (B) Zeta potential measurements of the same 
samples are shown. A noticeable difference between end capped 72 kDa molecular 
weight polymers and lower molecular weight 50 kDa PLGA’s was noticed (P = 
0.039) . This difference was even more apparent in the polyplex loaded nanospheres 
(P =0.0002 ). (C) The encapsulation efficiencies of the same samples are shown. 50 
kDa PLGA polymers showed significantly higher encapsulation efficiencies 
compared to 72 kDa PLGA (P=0.018). (D) The PLGA mass yield for the same 
samples is shown. The yield for 72 kDa PLGA was moderately higher than for 50 
kDa PLGA polymers for both unloaded and loaded samples (P=0.021 and 0.0074 
respectively). Measurements from the 72 kDa and 50 kDa PLGA groups were 
repeated in triplicate from independently prepared samples (N=3). Measurements 
from the 18 kDa PLGA group were from a single sample.  
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 moderately higher in 72 kDa PLGA samples (60.5 ± 8.19% unloaded, 65.0 ± 3.6% 
polyplex loaded) compared to 50 kDa PLGA (41.0 ± 3.6% unloaded, 43.5 ± 6.7% 
polyplex loaded) and 17 kDa PLGA (39.5% unloaded, 41.7% polyplex loaded). 
Measurements from the 72 kDa PLGA and 50 kDa PLGA groups were repeated in 
triplicate (N=3) from independently prepared samples. Measurements from the 17 kDa 
PLGA group were made from a single prepared sample. 
 The characterization of nanospheres is more accurately described by the size 
distribution profiles. Figure 4-7A shows examples of size and polydispersity for 
unloaded, ESO loaded, and polyplex loaded nanospheres, formulated using 50 kDa 
molecular weight PLGA polymers. A much higher polydispersity of the polyplex 
loaded nanospheres is apparent, while ESO loaded nanospheres show relatively the 
same distribution. In order to confirm the results from DLS measurement, physical 
imaging of the nanospheres was performed. Figure 4-7B shows an example AFM 
image, taken from a sample of polyplex loaded nanospheres, that confirms the actual 
size of the nanospheres is comparable to the values indicated by DLS. 
  The release rate of ESO from the nanospheres was measured for samples made 
from each of the three different PLGA polymers. Figure 4-8 shows the percentage of 
ESO released over the course of 26 days. The overall release of ESO significantly 
increased with decreasing PLGA molecular weight, giving a maximum release of 38.0 ± 
2.0% using 50 kDa PLGA, and 66.5 ± 1.0 % using 17 kDa PLGA. No noticeable 
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Figure 4-7. Size and polydispersity of PLGA nanospheres formulated with 50 
kDa non-endcapped PLGA (A) Examples of size and polydispersity for 
unloaded, ESO loaded, and polyplex loaded nanospheres are shown, 
formulated using 50 kDa molecular weight PLGA polymers. A noticeably 
higher polydispersity of the polyplex loaded nanospheres (blue) is apparent 
compared to both unloaded (red) and ESO loaded (green) nanospheres. (B) 
Atomic force microscopy (AFM) was used to confirm DLS measurements. 
AFM imaging was performed by Soonjin Hong in the lab of Dr. Kenneth 
Barbee (Drexel University) 
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Figure 4-8. Release kinetics of ESO from nanospheres formulated with PLGA 
polymers with molecular weights of 50 kDa (gray), and 17 kDa (green) 
Measurements were repeated in triplicate for each group (N=3) 
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B 
Figure 4-9. Comparison of unencapsulated and PLGA encapsulated 
PEI25Krho(PEG5K)10-ESO polyplex distribution through muscle tissue. Single 
injections of 15 μl containing the equivalent of 5 μg ESO were injected into 
the TA muscle of mdx mice. (A) Unencapsulated polyplex injections show a 
high accumulation of rhodamine fluorescence at the site of injection. (B) 
PLGA encapsulated polplex is able to disperse through muscle tissue away 
from the site of injection 
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release was seen using the 72 kDa ester endcapped PLGA (data not shown). The burst 
release in the first 24 hours from 17 kDa PLGA was nearly 20%, approximately 4 times 
more than for 50 kDa PLGA (5%). 
 The distribution of the polyplexes through the muscle tissue was evaluated using 
encapsulated rhodamine labeled PEI25KRho(PEG5K)10 polymer. IM injections of 
unencapsulated PEI25KRho(PEG5K)10 or PLGA encapsulated PEI25KRho(PEG5K)10 
were done in mdx mice. Fluoresence imaging of the rhodamine labeled showed the 
unecapsualted PEI25KRho(PEG5K)10 polymer was not able to diffuse far from the site of 
injection  (Figure 4-9A ) whereas encapsulated polyplexes were more dispersed 
through the muscle section (Figure 4-9B).   
 
Discussion 
 The goal of this study was to evaluate the feasibility of encapsulating PEG-PEI-
ESO polyplexes within biodegradable PLGA nanospheres with the idea that these 
compounds may eventually be tested for improving in vivo delivery of cationic 
polyplexes. Although there are many studies available on encapsulating cationic 
polymers complexed to DNA [for review see  [138]], all of these studies focus on 
microspheres that are unsuitable for in vivo delivery. This is the first study to 
demonstrate the feasibility of encapsulating PEG-PEI-ESO complexes fully within 
nanospheres, with average diameters less than 300 nm, which mask the positive surface 
charge and allow sustained release of cationic polyplexes. 
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 The feasibility of encapsulating nanospheres was first evaluated using a protocol 
(Cohen-Sacks et al) that has previously shown to encapsulate an oligonucleotide within 
nanospheres for treatment of restenosis [137]. The original protocol used produced 
unloaded and ESO loaded nanospheres roughly 300 nm in size, comparable to the 
results reported by Cohen-Sacks [137]. The results from the polyplex loading, however, 
produced slightly larger (~350 nm). Also, a significant population of larger particles 
was always apparent in each of the samples prepared with PEI25K(PEG5K)10 that was 
not apparent in unloaded or ESO loaded samples (data not shown). While these particles 
could easily be filtered out using a 1 µm syringe filter, the polydispersity of samples 
loaded with PEI25K(PEG5K)10 remained extraordinarily high. This result is consistent 
with De Rosa et al [132, 139] who showed a dramatic increase in PLGA microsphere 
size when PEI was introduced into the primary aqueous phase. One of the possible 
reasons for the increase in nanosphere size is that PEI25K(PEG5K)10, while introduced 
into the primary aqueous phase, is also soluble in the organic phase and thus can 
become incorporated within it. This may make it more difficult for PLGA polymers to 
group together when stabilized in PVA by hydrophobic interaction and consequently 
cause an enlargement of the nanospheres. Alternatively, surface bound 
PEI25K(PEG5K)10 copolymers contain many amine groups per molecule that may 
interact with carboxylic acid groups on the nanosphere surface. Thus, surface bound 
PEI can potentially act as a crosslinker between nanospheres. Crosslinked nanospheres 
may appear as larger single entities when size anlysis is performed by DLS and may be 
the cause of the large aggregate structures that are apparent in the samples. Even after 
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filtering the nanospheres through a 1 μm syringe filter, the polydispersity of the 
polyplex loaded samples remained unsuitably high requiring further modification of the 
formulation parameters.  
  To reduce polydispersity and nanosphere size, pilot experiments were 
performed by changing the sonication amplitude and PVA concentrations (Figure 4-3), 
the parameters thought to be most critical in determining resulting nanosphere size 
[133, 138]. Predictable trends of decreased nanosphere diameters were seen with 
increasing PVA and sonication amplitudes. While the combination of increased 
sonication amplitude and PVA concentration moderately reduced the mean diameter 
and polydispersity of the sample, large particles still appeared when PEI25K(PEG5K)10 
was introduced into the system (data not shown). It was inferred that the formulation 
procedure could be further improved by reducing the sonication vessel size to produce 
more homogenous application of sonication energy. This produced dramatically smaller 
nanospheres and lower polydispersity of the sample (Figure 4-4). The pilot studies, 
taken together, determined the optimum parameters for nanosphere formulation and 
demonstrated the feasibility of encapsulating polyplexes within nanospheres suitable for 
being delivered to muscle tissue. 
 The availability of a wide variety of chemically modified PLGA polymer is an 
attractive aspect of using PLGA nanospheres as a carrier. The effect of altering the 
PLGA structure has important implication in designing a suitable gene delivery vector. 
Simple chemical modifications to PLGA, such as ester endcapping of the free 
corboxlyic acid group on PLGA can have a dramatic effect on the properties of 
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nanospheres and the encapsulated polyplexes. Non-endcapped PLGA polymers (50 kDa 
and 17 kDa) showed almost identical size distributions compared to the 72 kDa 
endcapped PLGA for unloaded and polyplex loaded nanospheres (Figure 4-6A). 
However, the surface charge, encapsulation, and yield, of the nanospheres showed stark 
differences . Suprisingly, unloaded end-capped PLGA nanospheres showed zeta 
potentials only slightly lower than non-endcapped nanospheres (Figure 4-6B). The 
reason for this observation is not known.  More surprisingly, the surface charge of ester 
endcapped PLGA nanospheres loaded with polyplex is much less, whereas the surface 
charge of uncapped PLGA nanospheres remains the same. The amelioration of the 
surface charge may be due to excess un-encapsulated cationic PEI25K(PEG5K)10 
adsorbed to the surface of the nanospheres during the formulation procedure.  Non-
endcapped PLGA polymers appear to encapsulate polyplexes with a much better 
efficiency, which may eliminate any effect of surface adsorbed PEG-PEI. The higher 
level of entrapment is most likely attributed to interaction between carboxylic acid end 
groups on the PLGA interacting with amine groups on the PEG-PEI. This idea is 
supported by De Rosa et al [132] [139] who showed significantly higher encapsulation 
efficiency of ESO into PLGA microspheres in the presence of PEI. The increased level 
of ESO entrapment in the nanospheres highlights another advantage to using PEG-PEI 
in PLGA formulations. 
 The availability of a wide variety of different molecular weights is another 
advantage of using PLGA delivery systems. PLGA molecular weight, as well as end-
capping, has a dramatic effect on the release profiles of encapsulated compounds. High 
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molecular weight 72 kDa end-capped PLGA is far more hydrophobic and less 
susceptible to degradation than the non-endcapped PLGA nanospheres. This is clearly 
demonstrated by the fact that there was no noticeable release of polyplex from the 
nanospheres (data not shown). Non-endcapped, on the other hand, begins to release 
polyplex within 24 hours of being in solution. In fact, the molecular weights of the 
polymers seem to only affect the release kinetics of the polyplex without altering any of 
the other physical properties of the nanospheres. This can be seen by comparing the 
samples formulated with the 17 kDa PLGA and 50 kDa PLGA , which shows that the 
only noticeable difference is the rate of ESO release. The ability to tailor a single 
property, namely release kinetics, without affecting any of the other physical 
characteristics demonstrates the versatility of PLGA as a carrier for polyplex delivery. 
  The overall result of this study produced polyplexes encapsulated into PLGA 
nanospheres that demonstrated much better in vivo distribution in muscle tissue (Figure 
4-9). This result strongly supports the hypothesis that the surface charge of cationic 
complexes is responsible for their poor distribution profile. Furthermore, this result 
illustrates the potential for delivering more cationic polyplexes in vivo without 
modulating the surface properties of PEI. More experiments are necessary to 
systematicllay evaluate the levels of dystrophin expression following injections of 
encapsulated PEG-PEI-ESO polyplexes.  
 One of the most practical applications of PLGA nanospheres is to utilize the 
degradable properties for sustained drug delivery. This study has shown that PEG-PEI-
ESO’s can be efficiently encapsulated into small nanospheres that can readily release its 
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contents over a variable time range. This has practical implications in treating organs 
afflicted by DMD through localized injections to the heart and diaphragm tissues where 
PEG-PEI-ESO’s can continuously be released to transfect tissue without the need for 
repetitive injections that damage the tissue. Similarly, intramuscular injections to limb 
muscles can be performed for long term release of PEG-PEI-ESO’s. Further studies 
need to be done to evaluate the long term effects and the feasibility of localized delivery 
of PEG-PEI-ESO’s for therapeutic treatment of DMD. 
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CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTION 
 
Conclusion 
 
 The overarching significance of this project is the development and 
implementation of synthetic biopolymers complexed, with ESO’s, that provide a 
realistic opportunity to express functional levels of dystrophin to skeletal muscle and 
significantly ameliorate pathological symptoms of DMD. The results of this project 
serve to further the advancement of a specific class of polymers, namely PEG-PEI 
based copolymers, as superior transfection agents that have a realistic potential to 
provide a safe and cost effective alternative to viral vector gene therapy treatment of 
DMD.  
 The initial aim of this study (Chapter 2) was to establish that PEG-PEI co-
polymers were able to transfect mature skeletal muscle in culture and enhance AO 
delivery to the nucleus, which has not been previously demonstrated. The results of the 
study in chapter 2 show that PEG-PEI copolymers function as high-capacity carriers 
that facilitate efficient delivery of ESO to nuclei of mature myofibers isolated from mdx 
mice. Importantly, the ESO transfection using a PEG-PEI co-polymer demonstrated an 
enhanced ESO uptake in the nucleus while showing nuclear exclusion of the polymer, 
which accumulated in the perinuclear regions. Additionally, PEG-PEI did not seem to 
affect the morphology of the cell, indicating a lack of cytotoxicity. An unintentional 
increase in nuclear uptake of ESO was observed using rhodamine labeled PEG-PEI 
compounds which served to demonstrate the fundamental importance of surface 
chemistry in designing gene delivery vectors. The major limitation of this study was the 
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inability to maintain mature skeletal muscle in culture for prolonged periods of time 
needed to measure dystrophin protein recovery. In order to do so, the focus of this 
project was shifted to in vivo delivery of PEG-PEI-ESO complexes to evaluate overall 
levels of dystrophin recovery.  
Despite the efficient nuclear uptake of ESO observed in the in vitro studies, pilot 
studies using the same polymers did not show a quantifiable level of dystrophin 
expression when applied directly to skeletal muscle in vivo. The second aim of this 
project (Chapter 3) was to develop improved PEG-PEI copolymers for functional 
delivery of ESO’s to skeletal msucle in vivo. The PEG-PEI copolymer used in chapter 
3 utilizes a low molecular weight PEI based polymer with high molecular PEG (PEI2K-
(PEG5K)10)  characterized by a having a small size, low surface charge, and highly 
stable interaction with ESO’s. The low molecular weight PEI2K polymer in this study 
showed much greater transfection efficiencies than high molecular weight PEI25K 
based polymers. Modifications of the basic PEG-PEI structure with TAT peptides 
showed a significantly improved number of dystrophin positive fibers and enhanced 
dystrophin expression. The levels of dystrophin expression achieved using this TAT-
modified polymer showed some of the highest reported levels of dystrophin expression 
using 2’OMe AO chemistry. The major limitation of this study was the inability to 
delivery ESO uniformly throughout the muscle tissue, thus limiting the maximum 
amount of dystrophin expression that could be achieved.  
The final aim of this study (Chapter 4) is largely exploratory research into 
potentially overcoming the in vivo limitations of cationic PEG-PEI-ESO compounds. 
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Encapsulation of PEG-PEI-ESO’s into biodegradable PLGA nanospheres is a novel 
approach to delivering PEG-PEI polyplexes in vivo without needing to modify the PEG-
PEI structure. In this study, the feasibility of encapsulating PEG-PEI-ESO’s into small 
nanospheres was successfully accomplished by sytematically varying PLGA molecular 
weights, chemistry, and formulation parameters to produce optimally formulated 
nanospheres with average diameters less than 300 nm in size. The results of this study 
demonstrate the potential of utilizing PLGA nanospheres to shield the surface charge of 
PEG-PEI-ESO polymers for improved in vivo polyplex delivery without altering the 
surface of the PEG-PEI co-polymers. Experiments using PLGA encapsulated PEG-PEI-
ESO compounds is an ongoing project that has significant potential for sustained long-
term delivery of ESO’s to skeletal muscle. Future experiments will evaluate the long 
term functional effects of dystrophin expression using a variety of PLGA encapsulated 
PEG-PEI co-polymers encapsulated into PLGA nanospheres.    
 
Implications in Non-viral Gene Therapy 
 
 The work in this project furthers the advancement towards developing of novel 
non-viral gene therapy vectors that have a realistic potential for delivering therapeutic 
ESO’s to skeletal muscle. The experiments in these studies are largely meant as a 
“proof of principle” that demonstrate the viability of PEG-PEI compounds as a 
therapeutic agent. Still, many obstacles to systemic gene delivery must be overcome 
before PEG-PEI co-polymers will be viewed as realistic alternative to viral vector 
approaches. The use of PEG-PEI as a platform for developing next generation 
transfection agents is discussed in the subsequent section (Future Direction).  
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 The overall significance of this project is not limited to the scope of treating 
DMD. Although the experiments in this project predominantly involve transfecting 
skeletal muscle, the potential applications of the PEG-PEI polymers developed can have 
a much broader application. It is expected that the improvements in the PEG-PEI 
compounds which demonstrated far superior transfection efficiencies in muscle cells 
can also transfect other tissue for treating non-DMD related diseases. Diseases which 
involve alternatively splicing and can potentially be treated with ESO’s are increasingly 
being identified [140] and should be explored using PEG-PEI based transfection agents. 
Currently, the compounds developed in this project are being evaluated as carriers for 
an ESO that can potentially treat spinal muscular atrophy (SMA), a lethal 
neurodegenerative disease in humans which is caused by a mutation in the SMN1 gene. 
Additionally, the PEG-PEI polymers developed in this project are applicable for the 
delivery of other nucleic acid compounds, such as increasingly popular siRNA for 
knockdown of protein expression and other applications.  
 
Systemic Delivery of PEG-PEI-ESO compounds 
 The overall goal of developing PEG-PEI carriers for ESO’s is to create a 
clinically viable treatment for DMD and other genetic diseases. Although no systemic 
studies were performed in this project, the work here serves as a platform for 
developing improved PEG-PEI compounds capable of systemic delivery. The results of 
chapter 4 demonstrate the feasibility of encapsulating and releasing PEG-PEI-ESO 
polyplexes within a biodegradable and biocompatible capsules small enough to circulate 
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through capillary beds and improve the distribution of cationic compounds. Further 
modifications to the nanospheres are likely required for prolonged circulation and organ 
specific targeting. Surface modifications of PLGA nanospheres, namely pegylation, 
have demonstrated reduced serum binding and uptake by macrophages [141] resulting 
in a dramatic increase in circulation time [142]. Antibody or peptide conjugations to the 
nanospheres, such as HIV-tat derived peptides, are able to promote transcytosis and 
intracellular uptake of large cargo in a wide variety of tissue [143] which can potentially 
make PLGA nanospheres far more efficient carriers. Further progress must be made 
before encapsulated PEG-PEI-ESO’s can be clinically relevant; however, this study 
demonstrates a strong potential of designing a superior carrier for systemic ESO 
delivery. 
  Systemic delivery of encapsulated polyplexes can be further improved using 
non-invasive techniques, such as ultrasound energy. Ultrasound responsive 
microbubbles in the presence of an acoustic field has repeatedly demonstrated to be 
useful for organ specific drug and nucleic acid delivery applications [144-146], even to 
skeletal muscle [34]. The use of ultrasound is a cost-effective and non-invasive method 
of permeating endothelial tissue and promoting macromolecule uptake at specific areas 
in the body. This has important applications for the delivery of therapeutic drugs, 
plasmid DNA’s, or oligonucleotides, which may be unable to penetrate specific organs 
when delivered systemically. The use of ultrasound to promote the delivery of 
encapsulated PLGA polyplexes to heart and diaphragm tissue has realistic potential for 
delivering ESO’s systemically and alleviating the symptoms of DMD.   
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Future Direction  
 The limiting factors in non-viral gene delivery have been well established in 
recent reviews [9, 88] as well as in the Chapter 1 of this thesis. The development of 
highly stable, amine rich, PEGylated PEI based structures overcomes several of these 
barriers, however the limitations to the PEG-PEI systems should be further addressed. 
Recommendations and concepts for future direction of this work are discussed here to 
suggest ways to further enhance PEG-PEI capacity for targeted delivery and 
controllable release of ESO’s for clinical treatment of DMD. 
 
Next Generation Compounds 
Biodegradable PEG-PEI co-polymers 
 An important point in this study that warrants further investigation is the release 
of ESO’s from their PEG-PEI carriers. Clearly it was demonstrated in Chapter 2 (and 
inferred in Chapter 3) that ESO’s are separated from their carrier and transloacted to 
the nucleus where they bind to their target pre-mRNA. It is also clear, however, that 
much of the ESO remains bound to polyplex in the perinuclear regions of the cell. The 
kinetics and mechanisms of ESO release are relatively unknown in the studies presented 
in this project, and may be a very limiting factor in their delivery to myonuclei. Due to 
the complex interactions with a wide variety of intracellular components, it is not 
entirely feasible to determine the kinetics or mechanism of intracellular ESO release.
 Recently there has been a strong push in the field to develop “smart” polymers, 
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composed of acid-labile or enzmatically cleavable linkages [63, 90]. These polymers 
are meant to effectively breakdown into small subunits within the late endosomes or 
lysosomes and consequently destabilize any interaction with DNA or oligonucleotides. 
Several recent studies have demonstrated the ability to reversibly-crosslink PEI  to form 
aggregate structures, which significantly improves the transfections efficiency of 
nucleic acid compunds compared to standard PEI 25K [147-149]. However, the cause 
of the improved transfection efficiencies that are observed could be due to the formation 
of larger aggregate structures calpable of delivering ESO more efficiently, as suggested 
in some studies [77, 117]. Nevertheless, the development of biodegradable PEG-PEI 
copolymers for ESO is a rationale approach to overcoming release issue that may be 
present in current polyplex systems. Furthermore, biodegradable PEI based transfection 
agents could ultimately play an import role in the alleviating any potentially hazardous 
long term effects caused by repeated use of non-degradable polymers.   
 
Cell Targeting and enhancing intracellular uptake of PEG-PEI 
 It is clearly demonstrated in Chapter 3 that the addition of HIV-TAT peptides 
to the surface of PEG-PEI polymers dramatically improves the transfection efficiency 
of the polyplex. This result, combined with the fact that addition of the TAT peptides 
did not destabilize the polyplex, indicates that multiple peptide functionalization of 
PEG-PEI polymers is a rationale approach to improving ESO delivery efficiency. In this 
project, only a single peptide was utilized in order to facilitate intracellular uptake. 
Several other peptides have been identified that could potentially increase transfection 
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efficiency as well, such as pH response peptides and other peptides that may disturb 
endosomal membranes [150-152]. Additionally, nuclear localization of molecules have 
reportedly been enhanced by nuclear localization signal (NLS) peptides that can be 
conjugated to ESO’s [28]. The versatility of PEG-PEI compounds allows for the 
combination of multiple peptides to be conjugated to the amine rich surface of the co-
polymer, enabling a cooperative effect of peptides with different functions. The 
identification and utilization of a variety of peptide modified PEG-PEI co-polymers will 
likely produce far superior ESO transfection agents in next generation polymer design.  
Conclusion 
 Overall, the experiments in this project demonstrated the potential of PEG-PEI 
co-polymers to be efficient nucleotide carriers for to skeletal muscle both in vivo and in 
vitro. Although the development of PEG-PEI gene delivery vehicles is still in its 
infancy stage, the versatility of carrier system will undoubtedly begin to produce 
dramatic improvements in cell transfection capabilities. By focusing efforts on creating 
degradable cationic polymers and utilizing novel peptides to enhance ESO delivery, 
next generation PEG-PEI polymers can be developed in the near future that will likely 
attract attention in the gene therapy field as a potent and cost effective method of 
treating a wide variety of genetic disorders.      
  
94
List of References 
 
 
 
 
 1.  Watchko J, O'Day T, Wang B, Zhou L, Tang Y, Li J and Xiao X. Adeno-
associated virus vector-mediated minidystrophin gene therapy improves 
dystrophic muscle contractile function in mdx mice. Hum Gene Ther 13: 1451-
1460, 2002. 
 2.  Wang B, Li J and Xiao X. Adeno-associated virus vector carrying human 
minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse 
model. Proc Natl Acad Sci U S A 97: 13714-13719, 2000. 
 3.  England SB, Nicholson LV, Johnson MA, Forrest SM, Love DR, 
Zubrzycka-Gaarn EE, Bulman DE, Harris JB and Davies KE. Very mild 
muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 
343: 180-182, 1990. 
 4.  Winnard AV, Klein CJ, Coovert DD, Prior T, Papp A, Snyder P, Bulman 
DE, Ray PN, McAndrew P, King W and . Characterization of translational 
frame exception patients in Duchenne/Becker muscular dystrophy. Hum Mol 
Genet 2: 737-744, 1993. 
 5.  Chamberlain JS. Gene therapy of muscular dystrophy. Hum Mol Genet 11: 
2355-2362, 2002. 
 6.  Watchko JF, O'Day TL and Hoffman EP. Functional characteristics of 
dystrophic skeletal muscle: insights from animal models. J Appl Physiol 93: 
407-417, 2002. 
 7.  Walther W and Stein U. Viral vectors for gene transfer: a review of their use in 
the treatment of human diseases. Drugs 60: 249-271, 2000. 
 8.  Wells DJ, Wells KE, Asante EA, Turner G, Sunada Y, Campbell KP, Walsh 
FS and Dickson G. Expression of human full-length and minidystrophin in 
transgenic mdx mice: implications for gene therapy of Duchenne muscular 
dystrophy. Hum Mol Genet 4: 1245-1250, 1995. 
  
95
 9.  Boeckle S and Wagner E. Optimizing targeted gene delivery: chemical 
modification of viral vectors and synthesis of artificial virus vector systems. 
AAPS J 8: E731-E742, 2006. 
 10.  Hacein-Bey-Abina S, Von KC, Schmidt M, McCormack MP, Wulffraat N, 
Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R, 
Forster A, Fraser P, Cohen JI, de Saint BG, Alexander I, Wintergerst U, 
Frebourg T, Aurias A, Stoppa-Lyonnet D, Romana S, Radford-Weiss I, 
Gross F, Valensi F, Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva 
LE, Wissler M, Prinz C, Rabbitts TH, Le DF, Fischer A and Cavazzana-
Calvo M. LMO2-associated clonal T cell proliferation in two patients after gene 
therapy for SCID-X1. Science 302: 415-419, 2003. 
 11.  Fischer A, Hacein-Bey-Abina S, Lagresle C, Garrigue A and Cavazana-
Calvo M. [Gene therapy of severe combined immunodeficiency disease: proof 
of principle of efficiency and safety issues. Gene therapy, primary 
immunodeficiencies, retrovirus, lentivirus, genome]. Bull Acad Natl Med 189: 
779-785, 2005. 
 12.  Yoshimura M, Sakamoto M, Ikemoto M, Mochizuki Y, Yuasa K, Miyagoe-
Suzuki Y and Takeda S. AAV vector-mediated microdystrophin expression in 
a relatively small percentage of mdx myofibers improved the mdx phenotype. 
Mol Ther 10: 821-828, 2004. 
 13.  Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, van Ommen 
GJ, den Dunnen JT and van Deutekom JC. Antisense-induced multiexon 
skipping for Duchenne muscular dystrophy makes more sense. Am J Hum Genet 
74: 83-92, 2004. 
 14.  Mirabella M, Galluzzi G, Manfredi G, Bertini E, Ricci E, De LR, Tonali P 
and Servidei S. Giant dystrophin deletion associated with congenital cataract 
and mild muscular dystrophy. Neurology 51: 592-595, 1998. 
 15.  Marshall E. Gene therapy death prompts review of adenovirus vector. Science 
286: 2244-2245, 1999. 
 16.  Jiang Z, Schiedner G, van RN, Liu CC, Kochanek S and Clemens PR. 
Sustained muscle expression of dystrophin from a high-capacity adenoviral 
  
96
vector with systemic gene transfer of T cell costimulatory blockade. Mol Ther 
10: 688-696, 2004. 
 17.  Zaiss AK and Muruve DA. Immune responses to adeno-associated virus 
vectors. Curr Gene Ther 5: 323-331, 2005. 
 18.  Cerletti M, Negri T, Cozzi F, Colpo R, Andreetta F, Croci D, Davies KE, 
Cornelio F, Pozza O, Karpati G, Gilbert R and Mora M. Dystrophic 
phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-
mediated utrophin gene transfer. Gene Ther 10: 750-757, 2003. 
 19.  Gilchrist SC, Ontell MP, Kochanek S and Clemens PR. Immune response to 
full-length dystrophin delivered to Dmd muscle by a high-capacity adenoviral 
vector. Mol Ther 6: 359-368, 2002. 
 20.  van Deutekom JC and van Ommen GJ. Advances in Duchenne muscular 
dystrophy gene therapy. Nat Rev Genet 4: 774-783, 2003. 
 21.  Wilton SD and Fletcher S. Antisense oligonucleotides in the treatment of 
Duchenne muscular dystrophy: Where are we now? Neuromuscul Disord 15: 
399-402, 2005. 
 22.  van Deutekom JC, Bremmer-Bout M, Janson AA, Ginjaar IB, Baas F, den 
Dunnen JT and van Ommen GJ. Antisense-induced exon skipping restores 
dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet 10: 
1547-1554, 2001. 
 23.  Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, den Dunnen 
JT, Baas F, van Ommen GJ and van Deutekom JC. Therapeutic antisense-
induced exon skipping in cultured muscle cells from six different DMD patients. 
Hum Mol Genet 12: 907-914, 2003. 
 24.  Dunckley MG, Manoharan M, Villiet P, Eperon IC and Dickson G. 
Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by 
antisense oligoribonucleotides. Hum Mol Genet 7: 1083-1090, 1998. 
  
97
 25.  Mann CJ, Honeyman K, McClorey G, Fletcher S and Wilton SD. Improved 
antisense oligonucleotide induced exon skipping in the mdx mouse model of 
muscular dystrophy. J Gene Med 4: 644-654, 2002. 
 26.  Goyenvalle A, Vulin A, Fougerousse F, Leturcq F, Kaplan JC, Garcia L 
and Danos O. Rescue of dystrophic muscle through U7 snRNA-mediated exon 
skipping. Science 306: 1796-1799, 2004. 
 27.  Herweijer H and Wolff JA. Progress and prospects: naked DNA gene transfer 
and therapy. Gene Ther 10: 453-458, 2003. 
 28.  Niidome T and Huang L. Gene therapy progress and prospects: nonviral 
vectors. Gene Ther 9: 1647-1652, 2002. 
 29.  Somiari S, Glasspool-Malone J, Drabick JJ, Gilbert RA, Heller R, 
Jaroszeski MJ and Malone RW. Theory and in vivo application of 
electroporative gene delivery. Mol Ther 2: 178-187, 2000. 
 30.  Aihara H and Miyazaki J. Gene transfer into muscle by electroporation in 
vivo. Nat Biotechnol 16: 867-870, 1998. 
 31.  Bigey P, Bureau MF and Scherman D. In vivo plasmid DNA electrotransfer. 
Curr Opin Biotechnol 13: 443-447, 2002. 
 32.  Wang XD, Tang JG, Xie XL, Yang JC, Li S, Ji JG and Gu J. A 
comprehensive study of optimal conditions for naked plasmid DNA transfer into 
skeletal muscle by electroporation. J Gene Med 2005. 
 33.  Liang HD, Lu QL, Xue SA, Halliwell M, Kodama T, Cosgrove DO, Stauss 
HJ, Partridge TA and Blomley MJ. Optimisation of ultrasound-mediated gene 
transfer (sonoporation) in skeletal muscle cells. Ultrasound Med Biol 30: 1523-
1529, 2004. 
 34.  Lu QL, Liang HD, Partridge T and Blomley MJ. Microbubble ultrasound 
improves the efficiency of gene transduction in skeletal muscle in vivo with 
reduced tissue damage. Gene Ther 10: 396-405, 2003. 
  
98
 35.  Shi F and Hoekstra D. Effective intracellular delivery of oligonucleotides in 
order to make sense of antisense. J Control Release 97: 189-209, 2004. 
 36.  Kurreck J. Antisense technologies. Improvement through novel chemical 
modifications. Eur J Biochem 270: 1628-1644, 2003. 
 37.  Marcusson EG, Yacyshyn BR, Shanahan WR, Jr. and Dean NM. Preclinical 
and clinical pharmacology of antisense oligonucleotides. Mol Biotechnol 12: 1-
11, 1999. 
 38.  Ravichandran LV, Dean NM and Marcusson EG. Use of antisense 
oligonucleotides in functional genomics and target validation. Oligonucleotides 
14: 49-64, 2004. 
 39.  Opalinska JB and Gewirtz AM. Nucleic-acid therapeutics: basic principles 
and recent applications. Nat Rev Drug Discov 1: 503-514, 2002. 
 40.  Goodchild J. Oligonucleotide therapeutics: 25 years agrowing. Curr Opin Mol 
Ther 6: 120-128, 2004. 
 41.  Dias N and Stein CA. Antisense oligonucleotides: basic concepts and 
mechanisms. Mol Cancer Ther 1: 347-355, 2002. 
 42.  Sazani P and Kole R. Therapeutic potential of antisense oligonucleotides as 
modulators of alternative splicing. J Clin Invest 112: 481-486, 2003. 
 43.  van Deutekom JC. Gene Therapy: The 'pro-sense' approach to Duchenne 
muscular dystrophy. Eur J Hum Genet 13: 518-519, 2005. 
 44.  Bremmer-Bout M, Aartsma-Rus A, de Meijer EJ, Kaman WE, Janson AA, 
Vossen RH, van Ommen GJ, den Dunnen JT and van Deutekom JC. 
Targeted exon skipping in transgenic hDMD mice: A model for direct 
preclinical screening of human-specific antisense oligonucleotides. Mol Ther 10: 
232-240, 2004. 
  
99
 45.  Adams AM, Harding PL, Iversen PL, Coleman C, Fletcher S and Wilton 
SD. Antisense oligonucleotide induced exon skipping and the dystrophin gene 
transcript: cocktails and chemistries. BMC Mol Biol 8: 57, 2007. 
 46.  Alter J, Lou F, Rabinowitz A, Yin H, Rosenfeld J, Wilton SD, Partridge TA 
and Lu QL. Systemic delivery of morpholino oligonucleotide restores 
dystrophin expression bodywide and improves dystrophic pathology. Nat Med 
12: 175-177, 2006. 
 47.  Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen RD and Wilton 
SD. Dystrophin expression in the mdx mouse after localised and systemic 
administration of a morpholino antisense oligonucleotide. J Gene Med 2005. 
 48.  Gebski BL, Mann CJ, Fletcher S and Wilton SD. Morpholino antisense 
oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. 
Hum Mol Genet 12: 1801-1811, 2003. 
 49.  McClorey G, Moulton HM, Iversen PL, Fletcher S and Wilton SD. 
Antisense oligonucleotide-induced exon skipping restores dystrophin expression 
in vitro in a canine model of DMD. Gene Ther 13: 1373-1381, 2006. 
 50.  Moulton HM, Fletcher S, Neuman BW, McClorey G, Stein DA, Abes S, 
Wilton SD, Buchmeier MJ, Lebleu B and Iversen PL. Cell-penetrating 
peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne 
muscular dystrophy) and inhibit murine coronavirus replication in vivo. 
Biochem Soc Trans 35: 826-828, 2007. 
 51.  Abes R, Arzumanov AA, Moulton HM, Abes S, Ivanova GD, Iversen PL, 
Gait MJ and Lebleu B. Cell-penetrating-peptide-based delivery of 
oligonucleotides: an overview. Biochem Soc Trans 35: 775-779, 2007. 
 52.  Blume G and Cevc G. Liposomes for the sustained drug release in vivo. 
Biochim Biophys Acta 1029: 91-97, 1990. 
 53.  Ulrich AS. Biophysical aspects of using liposomes as delivery vehicles. Biosci 
Rep 22: 129-150, 2002. 
  
100
 54.  Juliano RL and Akhtar S. Liposomes as a drug delivery system for antisense 
oligonucleotides. Antisense Res Dev 2: 165-176, 1992. 
 55.  Weyermann J, Lochmann D and Zimmer A. Comparison of antisense 
oligonucleotide drug delivery systems. J Control Release 100: 411-423, 2004. 
 56.  Jaaskelainen I, Monkkonen J and Urtti A. Oligonucleotide-cationic liposome 
interactions. A physicochemical study. Biochim Biophys Acta 1195: 115-123, 
1994. 
 57.  Matsuura M, Yamazaki Y, Sugiyama M, Kondo M, Ori H, Nango M and 
Oku N. Polycation liposome-mediated gene transfer in vivo. Biochim Biophys 
Acta 1612: 136-143, 2003. 
 58.  Kim JK, Choi SH, Kim CO, Park JS, Ahn WS and Kim CK. Enhancement 
of polyethylene glycol (PEG)-modified cationic liposome-mediated gene 
deliveries: effects on serum stability and transfection efficiency. J Pharm 
Pharmacol 55: 453-460, 2003. 
 59.  Zelphati O and Szoka FC, Jr. Intracellular distribution and mechanism of 
delivery of oligonucleotides mediated by cationic lipids. Pharm Res 13: 1367-
1372, 1996. 
 60.  Zaru M, Mourtas S, Klepetsanis P, Fadda AM and Antimisiaris SG. 
Liposomes for drug delivery to the lungs by nebulization. Eur J Pharm 
Biopharm 2007. 
 61.  Tseng WC, Tang CH, Fang TY and Su LY. Using disaccharides to enhance in 
vitro and in vivo transgene expression mediated by a lipid-based gene delivery 
system. J Gene Med 9: 659-667, 2007. 
 62.  Richardso P, Kren BT and Steer CJ. In vivo application of non-viral vectors 
to the liver. J Drug Target 10: 123-131, 2002. 
 63.  Wagner E. Strategies to improve DNA polyplexes for in vivo gene transfer: 
will "artificial viruses" be the answer? Pharm Res 21: 8-14, 2004. 
  
101
 64.  Thomas M and Klibanov AM. Non-viral gene therapy: polycation-mediated 
DNA delivery. Appl Microbiol Biotechnol 62: 27-34, 2003. 
 65.  Merdan T, Kopecek J and Kissel T. Prospects for cationic polymers in gene 
and oligonucleotide therapy against cancer. Adv Drug Deliv Rev 54: 715-758, 
2002. 
 66.  Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B 
and Behr JP. A versatile vector for gene and oligonucleotide transfer into cells 
in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A 92: 7297-
7301, 1995. 
 67.  Danielsen S, Strand S, de Lange DC and Stokke BT. Glycosaminoglycan 
destabilization of DNA-chitosan polyplexes for gene delivery depends on 
chitosan chain length and GAG properties. Biochim Biophys Acta 1721: 44-54, 
2005. 
 68.  Danielsen S, Maurstad G and Stokke BT. DNA-polycation complexation and 
polyplex stability in the presence of competing polyanions. Biopolymers 77: 86-
97, 2005. 
 69.  Choi YH, Liu F, Kim JS, Choi YK, Park JS and Kim SW. Polyethylene 
glycol-grafted poly-L-lysine as polymeric gene carrier. J Control Release 54: 
39-48, 1998. 
 70.  Dash PR, Read ML, Barrett LB, Wolfert MA and Seymour LW. Factors 
affecting blood clearance and in vivo distribution of polyelectrolyte complexes 
for gene delivery. Gene Ther 6: 643-650, 1999. 
 71.  Harada A, Togawa H and Kataoka K. Physicochemical properties and 
nuclease resistance of antisense-oligodeoxynucleotides entrapped in the core of 
polyion complex micelles composed of poly(ethylene glycol)-poly(L-lysine) 
block copolymers. Eur J Pharm Sci 13: 35-42, 2001. 
 72.  Bieber T, Meissner W, Kostin S, Niemann A and Elsasser HP. Intracellular 
route and transcriptional competence of polyethylenimine-DNA complexes. J 
Control Release 82: 441-454, 2002. 
  
102
 73.  Godbey WT, Wu KK and Mikos AG. Tracking the intracellular path of 
poly(ethylenimine)/DNA complexes for gene delivery. Proc Natl Acad Sci U S 
A 96: 5177-5181, 1999. 
 74.  Kichler A. Gene transfer with modified polyethylenimines. J Gene Med 6 Suppl 
1: S3-10, 2004. 
 75.  Suh J, Wirtz D and Hanes J. Efficient active transport of gene nanocarriers to 
the cell nucleus. Proc Natl Acad Sci U S A 100: 3878-3882, 2003. 
 76.  Wiethoff CM and Middaugh CR. Barriers to nonviral gene delivery. J Pharm 
Sci 92: 203-217, 2003. 
 77.  Wightman L, Kircheis R, Rossler V, Carotta S, Ruzicka R, Kursa M and 
Wagner E. Different behavior of branched and linear polyethylenimine for gene 
delivery in vitro and in vivo. J Gene Med 3: 362-372, 2001. 
 78.  Rejman J, Bragonzi A and Conese M. Role of clathrin- and caveolae-
mediated endocytosis in gene transfer mediated by lipo- and polyplexes. Mol 
Ther 12: 468-474, 2005. 
 79.  Rejman J, Oberle V, Zuhorn IS and Hoekstra D. Size-dependent 
internalization of particles via the pathways of clathrin- and caveolae-mediated 
endocytosis. Biochem J 377: 159-169, 2004. 
 80.  Zuhorn IS, Kalicharan R and Hoekstra D. Lipoplex-mediated transfection of 
mammalian cells occurs through the cholesterol-dependent clathrin-mediated 
pathway of endocytosis. J Biol Chem 277: 18021-18028, 2002. 
 81.  Jensen KD, Nori A, Tijerina M, Kopeckova P and Kopecek J. Cytoplasmic 
delivery and nuclear targeting of synthetic macromolecules. J Control Release 
87: 89-105, 2003. 
 82.  Lavigne MD and Gorecki DC. Emerging vectors and targeting methods for 
nonviral gene therapy. Expert Opin Emerg Drugs 11: 541-557, 2006. 
  
103
 83.  Ogris M, Walker G, Blessing T, Kircheis R, Wolschek M and Wagner E. 
Tumor-targeted gene therapy: strategies for the preparation of ligand-
polyethylene glycol-polyethylenimine/DNA complexes. J Control Release 91: 
173-181, 2003. 
 84.  Liang KW, Hoffman EP and Huang L. Targeted delivery of plasmid DNA to 
myogenic cells via transferrin-conjugated peptide nucleic acid. Mol Ther 1: 236-
243, 2000. 
 85.  Ogris M, Brunner S, Schuller S, Kircheis R and Wagner E. PEGylated 
DNA/transferrin-PEI complexes: reduced interaction with blood components, 
extended circulation in blood and potential for systemic gene delivery. Gene 
Ther 6: 595-605, 1999. 
 86.  Kursa M, Walker GF, Roessler V, Ogris M, Roedl W, Kircheis R and 
Wagner E. Novel shielded transferrin-polyethylene glycol-
polyethylenimine/DNA complexes for systemic tumor-targeted gene transfer. 
Bioconjug Chem 14: 222-231, 2003. 
 87.  Mukherjee S, Ghosh RN and Maxfield FR. Endocytosis. Physiol Rev 77: 759-
803, 1997. 
 88.  Clague MJ and Urbe S. The interface of receptor trafficking and signalling. J 
Cell Sci 114: 3075-3081, 2001. 
 89.  Klemm AR, Young D and Lloyd JB. Effects of polyethyleneimine on 
endocytosis and lysosome stability. Biochem Pharmacol 56: 41-46, 1998. 
 90.  Oishi M, Nagatsugi F, Sasaki S, Nagasaki Y and Kataoka K. Smart polyion 
complex micelles for targeted intracellular delivery of PEGylated antisense 
oligonucleotides containing acid-labile linkages. Chembiochem 6: 718-725, 
2005. 
 91.  Thomas M and Klibanov AM. Enhancing polyethylenimine's delivery of 
plasmid DNA into mammalian cells. Proc Natl Acad Sci U S A 99: 14640-
14645, 2002. 
  
104
 92.  Sonawane ND, Szoka FC, Jr. and Verkman AS. Chloride accumulation and 
swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. 
J Biol Chem 278: 44826-44831, 2003. 
 93.  Akinc A, Thomas M, Klibanov AM and Langer R. Exploring 
polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. 
J Gene Med 7: 657-663, 2005. 
 94.  Sung SJ, Min SH, Cho KY, Lee S, Min YJ, Yeom YI and Park JK. Effect of 
polyethylene glycol on gene delivery of polyethylenimine. Biol Pharm Bull 26: 
492-500, 2003. 
 95.  Petersen H, Fechner PM, Martin AL, Kunath K, Stolnik S, Roberts CJ, 
Fischer D, Davies MC and Kissel T. Polyethylenimine-graft-poly(ethylene 
glycol) copolymers: influence of copolymer block structure on DNA 
complexation and biological activities as gene delivery system. Bioconjug Chem 
13: 845-854, 2002. 
 96.  Petersen H, Fechner PM, Fischer D and Kissel T. Synthesis, 
Characterization, and Biocompatibility of Polyethylenimine-graft-poly(ethylene 
glycol) Block Copolymers. Macromolecules 35: 6867-6874, 2002. 
 97.  Forrest ML, Meister GE, Koerber JT and Pack DW. Partial acetylation of 
polyethylenimine enhances in vitro gene delivery. Pharm Res 21: 365-371, 
2004. 
 98.  Kunath K, von Harpe A, Fischer D and Kissel T. Galactose-PEI-DNA 
complexes for targeted gene delivery: degree of substitution affects complex 
size and transfection efficiency. J Control Release 88: 159-172, 2003. 
 99.  Lee KM, Kim IS, Lee YB, Shin SC, Lee KC and Oh IJ. Evaluation of 
transferrin-polyethylenimine conjugate for targeted gene delivery. Arch Pharm 
Res 28: 722-729, 2005. 
 100.  Ogris M, Steinlein P, Carotta S, Brunner S and Wagner E. 
DNA/polyethylenimine transfection particles: influence of ligands, polymer 
size, and PEGylation on internalization and gene expression. AAPS PharmSci 3: 
E21, 2001. 
  
105
 101.  Thomas M and Klibanov AM. Conjugation to gold nanoparticles enhances 
polyethylenimine's transfer of plasmid DNA into mammalian cells. Proc Natl 
Acad Sci U S A 100: 9138-9143, 2003. 
 102.  Shi L, Tang GP, Gao SJ, Ma YX, Liu BH, Li Y, Zeng JM, Ng YK, Leong 
KW and Wang S. Repeated intrathecal administration of plasmid DNA 
complexed with polyethylene glycol-grafted polyethylenimine led to prolonged 
transgene expression in the spinal cord. Gene Ther 10: 1179-1188, 2003. 
 103.  Fischer D, Osburg B, Petersen H, Kissel T and Bickel U. Effect of 
poly(ethylene imine) molecular weight and pegylation on organ distribution and 
pharmacokinetics of polyplexes with oligodeoxynucleotides in mice. Drug 
Metab Dispos 32: 983-992, 2004. 
 104.  Glodde M, Sirsi SR and Lutz GJ. Physiochemical Properties of Low and High 
Molecular Weight PEG-Grafted Poly(ethylene imine) Copolymers and their 
Complexes with Oligonucleotides. Biomacromolecules 7(1): 347-356, 2006. 
 105.  Hughes MD, Hussain M, Nawaz Q, Sayyed P and Akhtar S. The cellular 
delivery of antisense oligonucleotides and ribozymes. Drug Discov Today 6: 
303-315, 2001. 
 106.  Roth CM and Sundaram S. Engineering synthetic vectors for improved DNA 
delivery: insights from intracellular pathways. Annu Rev Biomed Eng 6: 397-
426, 2004. 
 107.  Dass CR. Vehicles for oligonucleotide delivery to tumours. J Pharm Pharmacol 
54: 3-27, 2002. 
 108.  Kaisto T, Rahkila P, Marjomaki V, Parton RG and Metsikko K. 
Endocytosis in skeletal muscle fibers. Exp Cell Res 253: 551-560, 1999. 
 109.  Kunath K, von HA, Petersen H, Fischer D, Voigt K, Kissel T and Bickel U. 
The structure of PEG-modified poly(ethylene imines) influences biodistribution 
and pharmacokinetics of their complexes with NF-kappaB decoy in mice. 
Pharm Res 19: 810-817, 2002. 
  
106
 110.  Brus C, Petersen H, Aigner A, Czubayko F and Kissel T. Physicochemical 
and biological characterization of polyethylenimine-graft-poly(ethylene glycol) 
block copolymers as a delivery system for oligonucleotides and ribozymes. 
Bioconjug Chem 15: 677-684, 2004. 
 111.  Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G, Molema G, Lu 
PY, Scaria PV and Woodle MC. Cancer siRNA therapy by tumor selective 
delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids 
Res 32: e149, 2004. 
 112.  Vinogradov SV, Batrakova EV and Kabanov AV. Nanogels for 
oligonucleotide delivery to the brain. Bioconjug Chem 15: 50-60, 2004. 
 113.  Jeong JH, Kim SW and Park TG. A new antisense oligonucleotide delivery 
system based on self-assembled ODN-PEG hybrid conjugate micelles. J Control 
Release 93: 183-191, 2003. 
 114.  Vinogradov SV, Bronich TK and Kabanov AV. Self-assembly of polyamine-
poly(ethylene glycol) copolymers with phosphorothioate oligonucleotides. 
Bioconjug Chem 9: 805-812, 1998. 
 115.  Vinogradov S, Batrakova E, Li S and Kabanov A. Polyion complex micelles 
with protein-modified corona for receptor-mediated delivery of oligonucleotides 
into cells. Bioconjug Chem 10: 851-860, 1999. 
 116.  Remy-Kristensen A, Clamme JP, Vuilleumier C, Kuhry JG and Mely Y. 
Role of endocytosis in the transfection of L929 fibroblasts by 
polyethylenimine/DNA complexes. Biochim Biophys Acta 1514: 21-32, 2001. 
 117.  Williams JH, Sirsi SR, Latta D and Lutz GJ. Induction of dystrophin 
expression by exon skipping in mdx mice following intramuscular injection of 
antisense oligonucleotides complexed with PEG-PEI copolymers. Mol Ther 
14(1): 88-96, 2006. 
 118.  Shukla R, Bansal V, Chaudhary M, Basu A, Bhonde RR and Sastry M. 
Biocompatibility of gold nanoparticles and their endocytotic fate inside the 
cellular compartment: a microscopic overview. Langmuir 21: 10644-10654, 
2005. 
  
107
 119.  Hainfeld JF and Powell RD. New frontiers in gold labeling. J Histochem 
Cytochem 48: 471-480, 2000. 
 120.  Ho A, Schwarze SR, Mermelstein SJ, Waksman G and Dowdy SF. Synthetic 
protein transduction domains: enhanced transduction potential in vitro and in 
vivo. Cancer Res 61: 474-477, 2001. 
 121.  Toro A and Grunebaum E. TAT-mediated intracellular delivery of purine 
nucleoside phosphorylase corrects its deficiency in mice. J Clin Invest 116: 
2717-2726, 2006. 
 122.  Lu QL, Mann CJ, Lou F, Bou-Gharios G, Morris GE, Xue SA, Fletcher S, 
Partridge TA and Wilton SD. Functional amounts of dystrophin produced by 
skipping the mutated exon in the mdx dystrophic mouse. Nat Med 9: 1009-1014, 
2003. 
 123.  Bala I, Hariharan S and Kumar MN. PLGA nanoparticles in drug delivery: 
the state of the art. Crit Rev Ther Drug Carrier Syst 21: 387-422, 2004. 
 124.  Panyam J and Labhasetwar V. Targeting intracellular targets. Curr Drug 
Deliv 1: 235-247, 2004. 
 125.  Astete CE and Sabliov CM. Synthesis and characterization of PLGA 
nanoparticles. J Biomater Sci Polym Ed 17: 247-289, 2006. 
 126.  Muller M, Voros J, Csucs G, Walter E, Danuser G, Merkle HP, Spencer 
ND and Textor M. Surface modification of PLGA microspheres. J Biomed 
Mater Res A 66: 55-61, 2003. 
 127.  Panyam J, Zhou WZ, Prabha S, Sahoo SK and Labhasetwar V. Rapid endo-
lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications 
for drug and gene delivery. FASEB J 16: 1217-1226, 2002. 
 128.  Bivas-Benita M, Romeijn S, Junginger HE and Borchard G. PLGA-PEI 
nanoparticles for gene delivery to pulmonary epithelium. Eur J Pharm 
Biopharm 58: 1-6, 2004. 
  
108
 129.  Shakweh M and Fattal E. Design and characterisation of poly(lactide-co-
glycolide) small particulate systems for the delivery of immunostimulant CpG 
oligonucleotide. J Nanosci Nanotechnol 6: 2811-2820, 2006. 
 130.  Moffatt S and Cristiano RJ. Uptake characteristics of NGR-coupled stealth 
PEI/pDNA nanoparticles loaded with PLGA-PEG-PLGA tri-block copolymer 
for targeted delivery to human monocyte-derived dendritic cells. Int J Pharm 
321: 143-154, 2006. 
 131.  Oster CG, Wittmar M, Bakowsky U and Kissel T. DNA nano-carriers from 
biodegradable cationic branched polyesters are formed by a modified solvent 
displacement method. J Control Release 111: 371-381, 2006. 
 132.  De Rosa G, Bochot A, Quaglia F, Besnard M and Fattal E. A new delivery 
system for antisense therapy: PLGA microspheres encapsulating 
oligonucleotide/polyethyleneimine solid complexes. Int J Pharm 254: 89-93, 
2003. 
 133.  Hsu YY, Hao T and Hedley ML. Comparison of process parameters for 
microencapsulation of plasmid DNA in poly(D,L-lactic-co-glycolic) acid 
microspheres. J Drug Target 7: 313-323, 1999. 
 134.  Oster CG and Kissel T. Comparative study of DNA encapsulation into PLGA 
microparticles using modified double emulsion methods and spray drying 
techniques. J Microencapsul 22: 235-244, 2005. 
 135.  Howard KA, Li XW, Somavarapu S, Singh J, Green N, Atuah KN, Ozsoy 
Y, Seymour LW and Alpar HO. Formulation of a microparticle carrier for oral 
polyplex-based DNA vaccines. Biochim Biophys Acta 1674: 149-157, 2004. 
 136.  Walter E and Merkle HP. Microparticle-mediated transfection of non-
phagocytic cells in vitro. J Drug Target 10: 11-21, 2002. 
 137.  Cohen-Sacks H, Najajreh Y, Tchaikovski V, Gao G, Elazer V, Dahan R, 
Gati I, Kanaan M, Waltenberger J and Golomb G. Novel PDGFbetaR 
antisense encapsulated in polymeric nanospheres for the treatment of restenosis. 
Gene Ther 9: 1607-1616, 2002. 
  
109
 138.  Capan Y, Woo BH, Gebrekidan S, Ahmed S and DeLuca PP. Influence of 
formulation parameters on the characteristics of poly(D, L-lactide-co-glycolide) 
microspheres containing poly(L-lysine) complexed plasmid DNA. J Control 
Release 60: 279-286, 1999. 
 139.  De Rosa G, Quaglia F, La Rotonda MI, Appel M, Alphandary H and Fattal 
E. Poly(lactide-co-glycolide) microspheres for the controlled release of 
oligonucleotide/polyethylenimine complexes. J Pharm Sci 91: 790-799, 2002. 
 140.  Garcia-Blanco MA, Baraniak AP and Lasda EL. Alternative splicing in 
disease and therapy. Nat Biotechnol 22: 535-546, 2004. 
 141.  Faraasen S, Voros J, Csucs G, Textor M, Merkle HP and Walter E. Ligand-
specific targeting of microspheres to phagocytes by surface modification with 
poly(L-lysine)-grafted poly(ethylene glycol) conjugate. Pharm Res 20: 237-246, 
2003. 
 142.  Li Y, Pei Y, Zhang X, Gu Z, Zhou Z, Yuan W, Zhou J, Zhu J and Gao X. 
PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and 
biodistribution in rats. J Control Release 71: 203-211, 2001. 
 143.  Brooks H, Lebleu B and Vives E. Tat peptide-mediated cellular delivery: back 
to basics. Adv Drug Deliv Rev 57: 559-577, 2005. 
 144.  Pitt WG, Husseini GA and Staples BJ. Ultrasonic drug delivery--a general 
review. Expert Opin Drug Deliv 1: 37-56, 2004. 
 145.  Paliwal S and Mitragotri S. Ultrasound-induced cavitation: applications in 
drug and gene delivery. Expert Opin Drug Deliv 3: 713-726, 2006. 
 146.  Pan H, Zhou Y, Sieling F, Shi J, Cui J and Deng C. Sonoporation of Cells for 
Drug and Gene delivery. Conf Proc IEEE Eng Med Biol Soc 5: 3531-3534, 
2004. 
 147.  Neu M, Sitterberg J, Bakowsky U and Kissel T. Stabilized nanocarriers for 
plasmids based upon cross-linked poly(ethylene imine). Biomacromolecules 7: 
3428-3438, 2006. 
  
110
 148.  Dong W, Jin GH, Li SF, Sun QM, Ma DY and Hua ZC. Cross-linked 
polyethylenimine as potential DNA vector for gene delivery with high efficiency 
and low cytotoxicity. Acta Biochim Biophys Sin (Shanghai) 38: 780-787, 2006. 
 149.  Thomas M, Ge Q, Lu JJ, Chen J and Klibanov AM. Cross-linked small 
polyethylenimines: while still nontoxic, deliver DNA efficiently to mammalian 
cells in vitro and in vivo. Pharm Res 22: 373-380, 2005. 
 150.  Turk MJ, Reddy JA, Chmielewski JA and Low PS. Characterization of a 
novel pH-sensitive peptide that enhances drug release from folate-targeted 
liposomes at endosomal pHs. Biochim Biophys Acta 1559: 56-68, 2002. 
 151.  Resina S, Abes S, Turner JJ, Prevot P, Travo A, Clair P, Gait MJ, Thierry 
AR and Lebleu B. Lipoplex and peptide-based strategies for the delivery of 
steric-block oligonucleotides. Int J Pharm 2007. 
 152.  Lee SH, Kim SH and Park TG. Intracellular siRNA delivery system using 
polyelectrolyte complex micelles prepared from VEGF siRNA-PEG conjugate 
and cationic fusogenic peptide. Biochem Biophys Res Commun 357: 511-516, 
2007. 
 153.  Rosenblatt JD, Lunt AI, Parry DJ and Partridge TA. Culturing satellite cells 
from living single muscle fiber explants. In Vitro Cell Dev Biol Anim 31: 773-
779, 1995. 
  
  
111
Appendix A 
List of Abbreviations  
 
 2’OMeAO     Oligonucleotides composed of 2’O-methyl substitutions on a 
   phosphorothioate backbone 
6-FAM  6-Carboxyfluorescein 
AAV   Adeno Associated Virus 
AO   Antisense Oligonucleotide 
BMD   Beckers Muscular Dystrophy -  A non-lethal form of Muscular 
   Dystrophy 
DGC    Dystroglycan complex – a dystrophin associated glycoprotein 
DLS   Dynamic Light Scattering  
DMD    Duschenne Muscular Dystrophy 
DMEM  Dulbecco's Modified Eagle's Medium 
EDC   (1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide Hydrochloride) 
EE   Encapsulation Efficiency 
ESO     Exon Skipping Oligonucleotide 
F127   A difunctional block copolymer surfactant used for a variety of 
   applications 
FBS   Fetal Bovine Serum 
FDB   Flexor digitorum brevus muscle – Muscle tissue located on the 
   sole of the foot 
HS   Horse Serum 
IM   Intramuscular 
ITS   insulin-transferrin-selenium 
Mdx   Dystrophin Null transgenic mouse 
N:P   Nitrogen:Phosphate ratio – measure of polymer to ESO ratio 
   when forming a polyplex  
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PEG     Polyethyleneglycol Polymer (linear with a single methoxy  
   endcapping unless otherwise stated) 
PEI     Polyethyleneimine Polymer (randomly branched unless otherwise 
   stated) 
PEG-PEI   Copolymer formed by the grafting of linear PEG chains to the 
   surface of PEI 
  
 CG-PEI2K(PEG5K)10   Colloidal Gold adsorbed to PEI2K(PEG5K)10   
 CG-TAT5- PEI2K(PEG5K)10  Colloidal Gold adsorbed to TAT5-PEG-PEI 
 TAT- PEI2K(PEG5K)10  PEI2K(PEG5K)10  polymers covalently coupled 
      with TAT peptides at a 1:1 peptide to polymer 
     ratio 
 TAT5- PEI2K(PEG5K)10 PEI2K(PEG5K)10  polymers covalently coupled 
     with TAT peptides at a 5:1 peptide to polymer 
     ratio 
 PEI25K(PEG5K)10    A specific formulation of PEG-PEI composed of 
     25 kDa PEI with ten 5 kDa linear PEG chains 
     attached to the surface 
 PEI25Krho(PEG5K)10  Rhodamine Labeled PEI25K(PEG5K)10 
 PEI2K(PEG5K)10  PEG-PEI composed of 2 kDa PEI with  
     ten 5 kDa linear PEG chains attached to the  
     surface 
 
PF   Paraformaldyhyde 
PLGA   Poly(lactice-co-glycolic) acid 
PNA    Peptide Nucleic Acid - an oligonucleotide analogue with an 
   uncharged backbone 
PMO    Phosphorodiamidate Morpholino – an oligonucleotide analogue 
   with an uncharged backbone 
PVA   Polyvinyl Alchol 
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RLU   Relative light Units 
TA   Tibialis Anterior Muscle 
TAT   Synthetic peptides corresponding to the HIV-TAT protein  
   transduction domain. The amino acid sequence of the peptide is 
   YGRKKRRQRRR 
TEM   Transmission Electron Microscopy 
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Appendix B 
 
Synthesis of PEG-PEI copolymers 
 
Materials 
 
Chemicals, reagents, and supplies 
1. Methoxypoly(ethylene glycol)-5000 (mPEG5000) and mPEG550 (Sigma, St. Louis, MO) 
2. Poly(ethylene imine)-25000(PEI25000) and PEI2000 (Sigma ) 
3. Hexane-1,6-diisocyanate (HMDI) (Sigma) 
4. Et2O (Sigma) 
5. Hexanes (Sigma) 
6. CHCl3 (>99.9% Sigma) 
7. NHS-rhodamine (Pierce Biotechnology, Rockford, IL) 
8. dialysis tubing (MW’s 10000 and 1000, Spectrum Laboratories, Rancho Dominguez, CA) 
9. nitrogen gas 
Instruments and equipment 
1. Reflux condenser 
2. Buchner funnel 
3. Filter paper (Fine grade Q2, Fisher Scientific, Rochester, NY) 
4. Rotary Evaporator (e.g., RV 06-ML, IKA Works, Wilmington, NC) 
5. Vacuum oven (e.g., Isotemp 281A, Fisher Scientific, Rochester, NY)  
6  Lyophilizer (e.g., VirTis, Model 10-100V, Gardiner, NY) 
 
Synthesis of PEI25K(PEG5K)10 
 PEG-PEI copolymers are prepared using a simple two-step procedure as previously 
described [96, 104].  This involves complexation of activated mPEG and PEI.  The 
synthesis is described to prepare about 3 g of final copolymer, although this is easily scaled 
and the exact yield will vary depending on the number of washes and desired purity of the 
sample. 
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1. mPEG5000 is activated with hexane-1,6-diisocyanate (HMDI), based on a previously 
reported procedure [96].  10 g of mPEG5000 is dissolved in 20 ml of CHCl3 and added 
to 40 mL of HMDI (~200× molar excess HMDI) in a 100 ml round-bottom flask, and is 
refluxed under nitrogen for 16 h 
2. The resultant amine-reactive mPEG-HMDI is recovered by precipitation in 500 ml of 
hexanes.  The precipitated polymer is isolated by vacuume filtration, using a Buchner 
funnel and fine filter paper, and then washed multiple times with hexanes to remove 
excess HMDI. 
3. The residue (mPEG-HMDI) is re-dissolved in a minimal amount of CHCl3 (10-15ml) 
and re-precipitated into hexanes (as in step 2) three times. 
4. The mPEG-HMDI is dried under vacuum for 48-72 h and stored at -20 °C in sealed 
vials under N2. 
5. 1 g of PEI25000 and 2.06 g of activated mPEG5000 are each dissolved in 50 ml of 
CHCl3, combined in a 250 ml round bottom flask, and refluxed for 16 h under N2. The 
gram quantities of reactants were chosen to give PEG:PEI molar ratio of 10 (Table 1). 
6. Copolymers are concentrated using a rotary evaporator and precipitated into Et2O and 
stored at -20 °C in sealed vials under N2. 
7. Stock solutions (typically 10 µg/µl) are prepared fresh each month by dissolving the 
copolymer in RNAase-free diH20, vortexing briefly, sonicating for 15 min, and then 
storing at 4°C. 
 
Synthesis of PEI2K(PEG5K)10 
The synthesis is exactly as for PEI25K(PEG5K)10 with the following differences. 
[Step 5]. 0.1 g of PEI2K and 2.6 g of activated mPEG5000 are dissolved in 50 ml of CHCl3 
each and refluxed for 16 h under N2. 
 
 Rhodamine-labeling of PEG-PEI copolymers 
 
An example of rhodamine labeling of PEI25K(PEG5K)10 at a ratio of 14 rhodamine’s 
per mole PEG-PEI is as follows: 
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1. Add 10 mg of PEI25K(PEG5K)10 (from stock solution) to 1X PBS (pH 8.0) to final 
volume of 1 mL. 
2. Add 1 mg of NHS-rhodamine to 100 µl of DMSO. 
3. Mix together the NHS-rhodamine and copolymer solutions and incubate on ice for 2 h. 
4. Remove un-reacted NHS-rhodamine by dialyzing for 48 h against large volume of di-
H2O (4 liters). Exhange water at 24 hour time point. 
5. Lyophilize the dialyzed solution and store at -20°C in sealed vials under N2. 
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Appendix C  
TAT Peptide conjugation to PEG-PEI  
 
 Peptide conjugations of the PEG-PEI copolymer were performed using carbodiimide 
chemistry using EDC to conjugate the COOH-terminus of the peptide to free primary amine 
groups on the copolymer 
 
Materials 
 
Chemicals, reagents, and supplies 
1. PEG-PEI copolymer 
2. (1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide Hydrochloride) EDC (Pierce 
Biotechnology, Rockford, IL) 
3. Dialysis tubing ( 10000 MWCO, Spectrum Laboratories, Rancho Dominguez, CA) 
4. 0.1 M (2-N-morpholinoethane sulfonic acid) MES buffer  pH 5.0 
5. Synthetic Peptide (YGRKKRRQRRR) (Genescript Piscataway, NJ, USA) 
 
Instruments and equipment 
1. Lyophilizer (e.g., VirTis, Model 10-100V, Gardiner, NY) 
 
Protocol for Peptide conjugation 
1. Dissolve 5 mg peptide in 400 μl of 0.1 M MES buffer mixed 
2.  Dissolve PEG-PEI in 500 μl MES buffer at either a 1:1 or 5:1 peptide to 
polymer molar ratio. 
3. Combine Peptide and PEG-PEI solution in 2 ml Eppindorf tube    
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4. Dissolve 10 mg EDC in 1 ml of ultrapure water. Add 100 μl of this solution 
immediately dropwise to the peptide polymer solution while rigorously mixing.  
5.  Incubated peptide PEG-PEI solution at room temperature for 2 h (end of end 
mixing) 
6.  Dialyze against 4 L of ddH20 at 4°C for at least 48 hours using 10 kDa MWCO 
dialysis tubing.  Exchange water every 24 hours. 
7. Freeze the dialyzed peptide polymer solution and lyophilize for at least 48 
hours. 
8. Recover the final product and store at -20 ºC until needed.  
  
119
Appendix D  
Preparation of PEG-PEI-ESO polyplexes 
 
Chemicals, reagents, and supplies 
1. All experiments use a 7.4 kDa 20 mer 2’O-methyl ESO (‘5-
UCCAUUCGGCUCCAAACCGG-3’) that is 5’ end-labeled with 6-FAM moiety. 
2. PEG-PEI copolymer 
3. Sterile 1X PBS or saline  
4.  1.5 ml Tubes (Eppendorf, Westbuty, NY) 
Instruments and equipment 
1. Bath sonicator (1510, Branson, Danbury, CT) 
 
Protocol for forming Polyplex 
 The following information is necessary to calculate the molar ratio of PEG-PEI to ESO 
at an nitrogen to phosphate ratio of 5. 
 
1. Mw of the ESO = 7.4 kDa 
2. Number of phosphate groups on the ESO (equal to 1 less than the number of base 
pairs) = 19 phosphate groups 
3. Mw of the copolymer  
a. PEI25K(PEG5K)10  = 79500 Da 
b. PEI2K(PEG5K)10   = 56500 Da 
4. Number of amine groups per mole of copolymer 
a. PEI25K(PEG5K)10  = 580 
b. PEI2K(PEG5K)10     = 46 
Example of the preparation of 100 µL of PEI25K(PEG5K)10-ESO polyplex solution at a ESO 
concentration of 1 µg/µL. 
1. Pipette 10 µL of ESO stock solution (10 µg/µL) and 72.6 µL of sterile PBS into an 
eppindorf tube. 
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2. Add 17.4 µL of PEI25K(PEG5K) copolymer stock solution (10 µg/µL) to the ESO 
solution while mixing. 
3. Sonicate using a standard bath sonicator for 30 min at room temperature. 
4. Incubate on ice for 30 min, and use within ~ 1 h. 
 
Preparation of 100 µL of  PEI2K(PEG5K)10-ESO polyplex solution at a ESO concentration of 1 
µg/µL would use the same steps, except 151 μl of PEI2K(PEG5K)10 of  stock solution (10 
μg/μL) would be used. 
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     Appendix E 
Isolating, Culturing, and Transfecting Primary Myofibers 
Materials 
 
Chemicals, reagents, and supplies 
1. DMEM (Mediatech Inc, Herndon. VA)  
2. 10% FBS (Mediatech) 
3. 50 µg/ml gentamycin sulfate (Thermo Fisher Scientific, Rochester, NY) 
4. 0.5 mg/ml type I collagenase (Sigma-Aldrich, St. Louis) 
5. Matrigel (1:6 dilution; BD Biosciences, San Jose, CA) 
6. Paraformaldyhyde (PF) (Sigma) 
7. Hoechst Dye (Molecular Probes, City, USA) 
8. Vectashield Mounting media (H-1000) (Vector Labs, Burlingame, CA) 
 
Instruments and equipment 
1. Laminar Flow Hood 
2. 9” Glass Pipettes (Thermo Fisher Scientific)  
3. Culture Plates (35 mm X 10 mm; BD Biosciences) 
4. 18 mm circular glass coverslips (Thermo Fisher Scientific) 
5. 37° CO2 Incubator (Lab-Line; Thermo Fisher Scientific) 
 
Protocol for transfection of mouse primary myofibers with PEG-PEI-AO polyplex 
 
1. Flexor digitorum brevis (FDB) muscles are pinned by their tendons in a sylgard-lined 
35 mm culture dish and incubated for 3 h at 37° (5% CO2) in culture media containing 
DMEM, 10% FBS, 50 µg/ml gentamycin sulfate, and 0.5 mg/ml type I collagenase. 
2. Following the collagenase digestion, gently triturate muscles with fire polished 9” glass 
pipettes [153]. Pipette dissociated fibers onto 15 mm glass cover slips coated with 
Matrigel (1:6 dilution) in 12 well plates containing 500 µl of DMEM (serum-free), and 
incubate overnight at 37 oC. 
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3. Replace culture media in each well with 500 µl of DMEM with 10% FBS and 50 µg/ml 
gentamycin. 
4. Prepare the PEG-PEI-AO polyplex as described in Appendix D except the final 
polyplex concentration will be 0.1 µg/uL of ESO.  For a 12-well plate prepare about 1.2 
mL of polyplex containing 12 µg of ESO. 
5. Remove 100 µl of media from each well and add it to 100 µl of polyplex solution. Mix 
the solution thoroughly and replace the total volume of 200 µl back into the well. 
6. Place 12 well plate into CO2 incubator. Replace each well with fresh media after 24 
hours. 
7. For fluorescence tracking, fix cells with 2 % paraformaldyhyde for 10 min and 
subsequently 4 % paraformaldyhyde for another 20 min. Counterstain with 1.2 µg/ml 
Hoechst dye and mount with Vectashield (H-1000). 
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Appendix F 
 
Polyplex Stability Assay 
 
 The relative stability of polyplexes is measured by measuring ESO released 
from PEG-PEI-ESO polyplexes in the presence of a competing polyanion as described 
by Glodde et al [104]. 
 
Chemicals, reagents, and supplies 
1. Heparin (American Pharmaceutical Partners, Inc., Schaumburg, IL) 
2. Agarose (Sigma Aldrich, St Lois, MO) 
3. TAE (40 mM Tris acetate, pH approx. 8.3, containing 1 mM EDTA.) 
4. Loading buffer (Sigma) 
Instruments and equipment 
1. Mini gel electrophoresis unit (B1A, Owl Separation Systems, Portsmouth, NH) 
2. Power supply 
3. PhotoMan Direct Copy Camera  (Hoefer, San Fransisco, USA)  
4. Macrovue UV-20 illuminator (Hoefer) 
 
The protocol for the polyanion competition assay is as follows: 
1. Prepare agarose gels (1.5% in TAE buffer). 
2. Prepare polyplex solutions (using a FAM-labeled ESO) as described in D except that 
final volumes should be 30 µl. 
3. Add heparin to the polyplex solution to a final concentration of 0-0.48 µg/µl, and 
incubate for 10 min. 
4. Add 2 µl of loading buffer and briefly vortex the samples. 
5. Load samples onto agarose gels and electrophorese at 100V for 25 min. 
6. Image the gel using Photoman Direct copy camera and quantify the intensity of the 
‘free AO” band. 
7. At a given heparin concentration, the percentage of AO dissociated from the polyplex is 
obtained by normalizing against the AO band measured from a sample containing AO 
only on the same gel.  
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Appendix G 
 
Protocol for Intramuscular Injections 
 
Chemicals, reagents, and supplies 
1.  Sterile insulin syringes: 27-28 gauge/0.5” and 31 gauge/0.5”; both with permanently attached 
needles (BD Biosciences, San Jose, CA) 
2.  0.9% sterile saline  
3.  70% ethanol (Thermo Fisher Scientific) 
4.  Opthalmic lubrication (Henry Schein, Melville, NY) 
5.  Sterile swabs (BD Biosciences) 
6.  Isopropyl alcohol swabs (BD Biosciences) 
Instruments and equipment 
1.  Narrow blade hair trimmers 
2.  Heated surface/Heating pad 
3.  Heat lamp 
4.  Tail vein restraint (Plas-Labs, Inc, Lansing, MI) or fabricated from a 50 mL conical tube 
 
 
Protocol for intramuscular injection of PEG-PEI-ESO in adult mice 
1. Prepare the PEG-PEI-ESO polyplex as described in Appendix D, using sterile saline as 
the diluent to bring to the appropriate volume. 
2. Load 15 µl of polyplex (containing 5 µg of ESO) into a 31 gauge-5/16” length insulin 
syringe with permanently attached needle and allow to come to room temperature.   
3. Anesthetize mice by intraperitoneal injection of a ketamine-xylazine mixture at an 
induction dose of 20-100 mg/kg. 
4. Place the mouse on a heated surface to maintain body temperature and apply opthalmic 
lubrication to both eyes with a sterile swab to ensure moisture during anesthesia. 
5. Shave the hair surrounding the injection site for visual confirmation of the appropriate 
muscle(s) and wipe the skin surface with isopropyl alcohol swabs to disinfect the area.  
6. Insert the needle through the skin along the mid-belly portion of the muscle and slowly 
expel the volume of polyplex, leaving the needle in place for 1 min to minimize leakage 
out the needle track. 
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7. Keep mice on the heated surface until awakening from anesthesia. 
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Appendix H 
 
Protein Extractions of frozen muscle sections 
 
 
Chemicals, reagents, and supplies 
1. Protein Extraction Buffer (PEB) (reagents and recipe listed at end of appendix) 
2. 0.5M Tris-base (pH 6.8) (Bio-Rad Laboratories, Hercules, CA) 
3. Sodium Dodecyl Sulfate (SDS) (Thermo Fisher Scientific, Rochester, NY) 
4. 2M Urea (Thermo Fisher Scientific) 
5. 1000x Mercaptoethanol (Sigma Aldrich, St Lois , MS) 
6. Glycerol (Thermo Fisher Scientific) 
7. 2% Bromophemol blue (Sigma) 
8. Protease inhibitors  
a. Sigma Cocktail (Sigma) 
b. Calpeptin (EMD chemicals, San Diego, CA) 
c. Calpain Inhibitor (EMD chemicals) 
Instruments and equipment 
1. Centrifuge (Eppindorf 5415D,Westbury , NY USA) 
2. 1.5 ml Eppindorf tubes (Eppendorf) 
Protocol for Dystrophin Protein Extraction 
 
1. Cut 60 μm section of frozen muscle and place in 1.5 μl eppindorf tube on       
dry ice.   
2. Make up protein extraction buffer prior to experiment & store in aliquots in        
-80° C  
3. Recipe: immediately before extraction, thaw 1 ml of PEB and add the following 
protease inhibitors 
a. Sigma Cocktail     5 μl  
b. Calpeptin       5 μl  
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c. Calpain Inhibitor  2.5 μl of 10 mM 
4. Add 50 µl  of PEB with protease inhibitors per (1) 60 µm section and pipet up 
and down to resuspend all tissue 
5. Incubate on ice for 30 mins 
6. Boil for 5 min 
7. Centrifuge for 5 min at 4000 g 
8. Remove supernatant and place in new 1.5 ml eppindorf tube 
9. Evaluate protein concentration using BCA protein assay kit using 5 μl from each 
sample. To the rest of the sample, add equal volume of loading Buffer and store 
in -80°C freezer 
 
Recipes 
 
Protein Extraction Buffer:   Final volume = 10 ml 
2.5 mL of 0.5M Tris-base (pH 6.8)                     
 0.4 g SDS                                                            
1.2 g Urea  
500 µl  1X mercaptoethanol  (1:1000 dilution of 
   1000X stock in ddH20) 
1g glycerol                                                       
 
2X Loading Buffer:    Final volume= 10 ml 
4 g SDS                                                                       
            500 μl  1X mercaptoethanol 
            2.5 ml of 0.5 ml Tris-base (pH 6.8)                              
            1 g glycerol                                                                   
            250 μl of 2% bromophemol blue (w/v in water) 
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Appendix I 
 
Quantification of the Dystrophin Protein 
Chemicals, reagents, and supplies 
1. Protein extraction solution from Appendix H 
2.  Kelidoscope protein standard (Molecular Probes, Carlsbad, CA) 
3. Running buffer (reagents and recipe listed at end of appendix) 
4. Transfer Buffer (reagents and recipe listed at the end of appendix) 
5. Odyssey blocking buffer (LI-COR Biosciences, Lincoln NE, USA) 
6. Blotting supplies:, sponges and filter paper (Amersham Biosciences, Piscataway, NJ) 
7. Nitrocellulose paper (Pierce Biotechnology, Rockford, IL) 
8. Horse Serum (Abcam, Cambridge, MA) 
9. MANDYS primary antibody (Sigma Aldrich, St Louis, MS) 
10. Donkey anti-goat IgG secondary antibody (800IR, LI-COR Biosciences) 
Instruments and equipment 
1. Gel electrophersis apparatus (Amersham Biosciences, Piscataway, NJ) 
2. Gel transfer apparatus (Amersham Biosciences, Piscataway, NJ) 
3. Odyssey infrared imaging system (LI-COR Biosciences) 
4. Odyssey application software (v2.1) 
 
Protocol for evaluating dystrophin expression 
 
1.  Pipet 10 μg of protein into all lanes that will contain a protein sample.  Load 5 μl of 
Kaleidoscope standard into the first well and 2.5 μl into the last well.   
2. Place electrodes over the electrode assembly, and run gel for 2 hours at 20mA constant 
current in cold room. 
3. Soak sponges, filter paper, nitrocellulose in transfer buffer. 
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4. Assemble “sandwich”; Loosen the gel from the gel plate and remove stacking gel. Cut 
the resolving gel from the glass plate. Transfer gel onto a single western blot filter 
paper.  Overlay the gel with second filter paper. Roll glass rod over the sandwiched 
nitrocellulose once in each direction. Lay second sponge on top of filter paper. Close 
sandwich and place into gel holder cassette, keeping nitrocellulose side of it oriented 
towards the clear side.   
5. Place gel holder cassette into the buffer tank, keeping the clear side towards the red 
(positive) electrode panel, place cooling unit (filled with ice) into the tank in bucket 
filled with ice, and run for 16 hours (960 minutes) at 30V in the cold room.  
6. When transfer is done, remove nitrocellulose paper and discard the gel. Cut 
nitrocellulose below the myosin band (top blue line on KDS standards) and place into 
multi-compartment tray. 
7. Block for 1 hour in Odyssey Blocking buffer with 3% Normal Horse serum (450 ul in 
15 ml Odyssey blocking buffer) on shaker.  
8. After one hour, mix primary MANDYS8 antibody (1:10) with Odyssey blocking buffer 
(100 uL with 4 ml blocking buffer)  and incubate for 1 hour 
10. Remove nitrocellulose from antibody solution.  Give membrane 3 X 5 minute washes 
in large volumes of TBS-T.   
11. Incubate nitrocellulose squares together in secondary antibody (5 ul of 1:10 Anti-Mouse 
800IR in 10 ml Blotto) for 1 hour at room temp on rocker.  If using fluorescent 
antibody, 4 uL into 20 mL Blotto.   
12. After one hour, give membrane 2 x 10 min washes in TBS-T, then a 15 min 
wash in TBS. 
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13. Image and quantify  dystrophin expression using odyssey infrared imaging 
system and application software 
 
 
Recipies: 
 10X Western Buffer pH 8.3 –     10X TBS pH 7.6 –
 Trizma base – 15.1 g    Trizma base – 24.2 g 
 Glycine – 72.1 g    NaCl – 80.1 g 
 Fill to 500 ml with dH20   1 M HCl – 3.16 mL   
       Fill to 1000 mL with dH20 
 
 
Transfer Buffer – Total volume = 800 mL 
 10X Western – 80 mL     
 ddH20 – 552 mL       
 Methanol – 160 mL      
 10% SDS – 8 mL     
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Appendix J 
 
Quantification of the Dystrophin by Immunostaining 
Chemicals, reagents, and supplies 
1. 1X PBS (Hyclone, Thermo Fisher Scientific, Walthman, MA) 
2. Triton X-100 (Sigma Aldrich, St. Louis, MO) 
3. 1% BSA (Jackson ImmunoResearch Laboratories, Inc. , West Grove, PA) 
4. 200uL of goat serum (Abcam, Cambridge, MA) 
5. Dystrophin Primary antibody (Abcam) 
6. Cy3 antigoat labeled secondary (Molecular Probes, Carlsbad, CA) 
7. Hoersche dye (Molecular Probes) 
8. Vectashield mounting medium (Vector Labs, Burlingame, CA) 
Instruments and equipment 
5. Immuno Pen (EMD Biosciences, San Diego, CA) 
6. Slide holders (Thermo Fisher Scientific) 
7. Odyssey infrared imaging system (LI-COR Biotechnology, Lincoln , Nebraska) 
8. Odyssey application software (v2.1) (LI-COR Biotechnology) 
 
Protocol for evaluating dystrophin expression 
 
1. Cut 10 μm sections of frozen muscle.  
2. Circle around tissue with Immuno pen, let pen air dry 
3. Place slides into holder, Rinse slides 2 x 5mins in PBS 
4. Rinse 2 X 5 in PBS w/ Triton (0.025% w/v) 
5. Block in 10% normal goat serum with 1% BSA in PBS for 1 hr at room temp 
(add 200uL of goat serum + 2mL 1% BSA in PBS) 
6. Drain slides for a few seconds, do not rinse 
7. Apply primary antibody – made up in PBS with 1% BSA (Abcam conc. 1 
μg/mL: add 10μL stock antibody to 2mLs of 1% BSA in PBS 
8. Incubate at 1hr, room temp 
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DARK STEPS 
9. Rinse 2 X 5mins in PBS with Triton 
10. Apply secondary antibody 1:500 in PBS (anti-rabbit, has fluorescent antibody 
already in it) with 1% BSA (2uL antibody in 1mL 1% BSA/PBS) for 1 hr at 
room temp. 
11. Rinse 1 X 5mins in PBS, then 5min in 2uL Hoersche (fridge) 1mL bicarb, then 
rinse 2 X 5mins in PBS 
12. Cover slip with one drop of Vectashield mounting medium 
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Appendix K 
 
Protocol for PLGA nanosphere formulation 
 
Chemicals, reagents, and supplies 
1. PLGA (Lakeshore Biomaterials, Birmingham, AL) 
a.  PLGA (50:50) DLG 5E – 72 kDa with Ester endcap 
b. PLGA(50:50) DLG 3.5A  - 50 kDa no Endcapping 
c. PLGA(50:50) DLG 2A  -   17 kDa no Endcapping 
2. Chloroform (>99.9) (Sigma Aldrich, St. Louis, MO) 
3. Poly Vinyl Alcohol (PVA) (88% Hydrolized 22 kDa MW;Acros Chemicals; Morris 
Plains NJ) 
4. 20 mer phosphothioated ESO (gift from the lab of Steve Wilton, PhD)  (‘5-
UCCAUUCGGCUCCAAACCGG-3’)  
 
Instruments and Equipment 
1. 20 ml glass scintillation vials (Thermo Fisher Scientific, Walthman MA ) 
2. 25 ml and 200 ml glass beakers 
3. 15 ml conical tubes (Thermo Fisher Scientific) 
4. 9 inch glass pipettes (ThermoFisher Scientific) 
5. 0.2 μm sterile bottle top filter (Nalgene, Rochester, NY) 
6. Heat and Stirplates (Corning, Corning, NY)   
7. Sonicator  with microtip attachment (Ultrasonics W-385; Heat Systems, Farmingdale, 
NY)  
8. Ultracentrifuge with swinging bucket rotor (Ultra 80; Sorvall, Ashville, NC) 
9. Centrifuge ( Allegra 21; Beckman Coulter, Fullerton, CA) 
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10. Benchtop Freeze Dryer (10-100V;Virtis, Gardiner, NY) 
11. Bath sonicator (1510, Branson, Danbury, CT) 
 
Protocol for Formulating PLGA nanospheres 
 
1. Prepare 5% (w/v) PVA Solution. Heat 500 ml of DI water to 90º C and slowly add 25 g 
PVA while stirring. Keep covered and let PVA dissolve for 3 hours at 90º C. Bring to 
room temperature and filter solution using 0.2 μm sterile bottle top filter. This solution 
is good for 1 month 
2. Weight out 70 mg of PLGA into a scintillation vial and dissolve in 2 ml of chloroform 
to form the primary organic phase. Let PLGA dissolve for at least 1 hour.  
3. Form polyplex as outlined in Appendix C with a final volume of 300 μl in sterile water 
to from the primary aqueous phase. Most of the experiments in this project used 1 mg 
of ESO and 1.845 mg PEI25K(PEG5K)10 .  Control studies use 1 mg of ESO alone or 
sterile water alone. 
4. Prepare and Ice bath using a 500 ml beaker filled with ice and water. Suspend a smaller 
25 ml beaker in the ice bath with 5 ml of water.  
5. Place scintilliation vial containing primary organic phase [step 2] in the ice bath and 
place in sonication box. Sonicate at an amplitude of 5 (~ 51 watts) for 20 seconds using 
pulsed sonication setting (80% duty cycle). 
6. Pipette the primary aqeuose phase [Step 4] into the scintillation vial [Step 5] and vortex 
for 30 seconds 
7. Sonicate the solution for 30 seconds at an amplitude of 5 using pulsed sonication 
setting. This forms the primary emulsion (w/o). 
8. Using a 9 inch glass pipette and bulb, add the primary emulsion to 25 ml of cold 5% 
PVA in a 50 ml beaker while stirring at 400 rpm forming the secondary emulsion 
(w/o/w) 
9. Remove stir bar and add separate the secondary emulsion into three scintillation vials 
with equal volumes (~ 9 ml) using 9 inch glass pipette. 
10. Sonicate the each solution in scintillation vial for 1 minute and recombine into 50 ml 
beaker. Let this solution stir overnight at 400 rpm to remove chloroform. Cover loosely 
with aluminum foil. 
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11. Pellet the nanospheres by centrifuging the solution for 1 hour at 20K rpm using the 
ultracentrifuge and swinging bucket rotor. 
12. Resuspend the solution in DI water and centrifuge again for an hour.  
13. Repeat step 12. 
14.  Using two spatulas, transfer the nanosphere pellet into a 15 ml conical tube and 
resuspend pellet in 5 ml of DI water. Resuspension requires rigourous vortexing (20 
minutes) and bath sonication. 
15. Remove large aggregates by centrifuging at 1000 rpm for 5 minutes. The nanospheres 
remain in the supernatant. Transfer supernatant to fresh conical tube and place in -80° C 
freezer. 
16. Lyophilize solution for at least 72 hours to remove water. 
17. Collect and weigh nanospheres to determine yield 
18. Store nanospheres in -20 °C freezer in dessicator until needed. 
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